ketorolac tromethamine profile

Ketorolac tromethamine, also known as ketorolac, is a nonsteroidal anti-inflammatory drug (NSAID) that is used to relieve pain and reduce inflammation. It is a derivative of the propionic acid NSAID, naproxen. Ketorolac tromethamine is available as an injection, tablet, and ophthalmic solution. It is commonly used for short-term pain relief, such as for postoperative pain, headache, and toothache. It is also used to treat inflammation associated with conditions such as arthritis. Ketorolac tromethamine works by inhibiting the production of prostaglandins, which are chemicals that cause pain and inflammation. The compound is synthesized through a multi-step process that involves starting with a benzene derivative and then modifying it with various chemical reagents to ultimately yield the desired structure. Ketorolac tromethamine is studied to understand its mechanism of action, develop new therapeutic applications, and explore potential adverse effects. It is important to note that ketorolac tromethamine has a number of potential side effects, including gastrointestinal bleeding, ulcers, and kidney problems. It is important to use this medication only as directed by a doctor.'

Ketorolac Tromethamine: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is a non-steroidal anti-inflammatory agent used for analgesia for postoperative pain and inhibits cyclooxygenase activity. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ketorolac tromethamine : An organoammonium salt resulting from the mixture of equimolar amounts of ketorolac and tromethamine (tris). It has potent non-sedating analgesic and moderate anti-inflammatory effects. It is used in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	84003
CHEMBL ID	1201124
CHEBI ID	6130
SCHEMBL ID	5036
MeSH ID	M0140754

Synonym
1h-pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro, (+-)-, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)
syntex
ketorolac tromethamine [usan]
acular preservative free
(+-)-5-benzoyl-2,3-dihydro-1h-pyrrolizine-1-carboxylic acid, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)
1h-pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro, (+/-)-, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol(1:1)
HMS3393P06
MLS000069689
smr000058461
ketorolac tromethamine
DIVK1C_000836
KBIO1_000836
ketorolac trometamol
lixidol
rox-828
acular pf
rox-888
droal
sprix
acuvail
acular ls
bppc
toratex
acular
dolac
tora-dol
BPBIO1_000922
IDI1_000836
EU-0100676
ketorolac tris salt, >=99%, crystalline
SPECTRUM_001578
PRESTWICK3_000929
cas-74103-07-4
NCGC00017135-01
BSPBIO_003575
LOPAC0_000676
BSPBIO_000838
SPECTRUM5_001273
PRESTWICK2_000929
MLS001401455
cpd000058461
74103-07-4
acular (tn)
ketorolac tromethamine (usp)
D00813
NCGC00094036-03
NCGC00094036-02
KBIO2_004626
KBIOSS_002058
KBIO3_002953
KBIO2_007194
KBIOGR_000849
KBIO2_002058
NINDS_000836
SPBIO_001596
SPECTRUM2_001598
SPECTRUM4_000215
SPBIO_003017
SPECTRUM3_001975
PRESTWICK0_000929
PRESTWICK1_000929
SPECTRUM1503925
NCGC00094036-01
ketorolac tris salt
MLS002222310
NCGC00016159-02
HMS2051P06
K 1136
HMS2093M05
nsc-758637
tarasyn
chebi:6130 ,
CHEMBL1201124
HMS502J18
HMS1570J20
HMS1922K22
2-amino-2-(hydroxymethyl)propane-1,3-diol; 5-benzoyl-2,3-dihydro-1h-pyrrolizine-1-carboxylic acid
A838011
5-benzoyl-2,3-dihydro-1h-pyrrolizine-1-carboxylate; 2-hydroxyethyl-bis(hydroxymethyl)ammonium;ketorolac tromethamine
HMS2097J20
HMS3262G13
ketorolac tromethamine [usan:usp]
4eve5946bq ,
tromethamine ketorolac
unii-4eve5946bq
nsc 758637
godek
tox21_113519
nsc758637
pharmakon1600-01503925
dtxcid301476271
dtxsid0045597 ,
tox21_110795
HMS2235N13
CCG-101006
CCG-39376
NCGC00016159-03
NCGC00016159-04
BCP9000811
ketorolac (toradol)
BCP0726000301
ketorolac (tromethamine salt) ,
FT-0630829
LP00676
S5698
HMS3373M06
ketorolac tromethamine [usp monograph]
ketorolac tromethamine [vandf]
ketorolac tromethamine [usp-rs]
ketorolac tromethamine [orange book]
ketorolac tromethamine [who-dd]
ketorolac trometamol [ep monograph]
2-amino-2-(hydroxymethyl)propane-1,3-diol (1rs)-5-benzoyl-2,3-dihydro-1h-pyrrolizine-1-carboxylate
1h-pyrrolizine-1-1h-pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro, (+/-)-, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)
ketorolac (+/-)-form tromethamine salt [mi]
omidria component ketorolac tromethamine
(+/-)-5-benzoyl-2,3-dihydro-1h-pyrrolizine-1-carboxylic acid, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)
ketorolac trometamol [jan]
ketorolac trometamol [mart.]
ketorolac tromethamine component of omidria
CS-1933
HY-B0138
BWHLPLXXIDYSNW-UHFFFAOYSA-N
NC00256
SCHEMBL5036
tox21_110795_1
NCGC00185990-04
tox21_500676
NCGC00261361-01
F0001-2390
2-amino-2-(hydroxymethyl)propane-1,3-diol 5-benzoyl-2,3-dihydro-1h-pyrrolizine-1-carboxylate
Q-201269
AKOS024386301
K0053
(+/-)-5-benzoyl-2,3-dihydro-1h-pyrrolizine-1-carboxylic acid tris salt
mfcd00887595
ketorolac tromethamine salt
ketorolac tromethamine, united states pharmacopeia (usp) reference standard
HMS3655E15
ketorolac trometamol for peak identification, european pharmacopoeia (ep) reference standard
ketorolac trometamol, european pharmacopoeia (ep) reference standard
ketorolac tromethamine, pharmaceutical secondary standard; certified reference material
ketorolac trometamol 1.0 mg/ml in methanol (as free acid)
sr-01000075948
SR-01000075948-6
SR-01000075948-8
SR-01000075948-1
HMS3714J20
SW197293-4
ketorolac tris salt;ketorolac tromethamine
Q27107089
AS-15193
SR-01000946595-1
sr-01000946595
BCP02917
ketorolac tromethamine;ketorolac tris salt;rs37619 tromethamine salt
M02042
2-amino-2-(hydroxymethyl)propane-1,3-diol;5-benzoyl-2,3-dihydro-1h-pyrrolizine-1-carboxylic acid
ketrolac.tromethamine salt
ketorolac trometamol for peak identification
ketorolactrissalt
ketotolac tromethamine
acunivive 30
ketorolac trometamol (ep monograph)
toronova suik
toronova ii suik
acunivive 15
ketorolac trometamol (mart.)
acunivive 60
ketorolac tromethamine (usan:usp)
readysharp ketorolac
ketorolac tromethamine (usp monograph)
ketorolac tromethamine (usp-rs)

Excerpt	Reference	Relevance
"Ketorolac tromethamine (KT) is a non-steroidal anti-inflammatory drug from the heteroaryl acetic acid derivatives family. "	( Ketorolac Tromethamine Loaded Nano-Spray Dried Nanoparticles: Preparation, Characterization, Cell Viability, COL1A1 Gene Simulation and Determination of Anti-inflammatory Activity by Çevikelli, T; Güven, UM; Kıyan, HT; Öztürk, AA; Tilki, EK, 2023)	3.8
"Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that is extensively used for the management of renal colic in the emergency department (ED). "	( Comparison of intravenous ketorolac at three doses for treating renal colic in the emergency department: A noninferiority randomized controlled trial. Ahmadi, A; Bahreini, M; Eidinejad, L; Mirfazaelian, H; Thiruganasambandamoorthy, V; Yazdchi, M, 2021)	2.06
"Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that provides postoperative pain control and reduces narcotic requirements. "	( Is ketorolac safe to use in plastic surgery? A critical review. Langstein, HN; Richards, BG; Schleicher, WF; Stephens, DM; Zins, JE, 2015)	1.86
"Ketorolac tromethamine is a potent analgesic NSAID that is known to cause gastrointestinal complications."	( Preclinical evaluation of dual action intranasal formulation intended for postoperative/cancer associated therapies. Ahmed, S; Badawi, AA; El-Nabarawi, MA; El-Setouhy, DA; Sallam, N, 2015)	1.14
"Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug that exhibits analgesic activity with no sedative or anxiolytic properties. "	( Comparison of the Pharmacokinetics of Ketorolac Tromethamine After Continuous Subcutaneous Infusion and Repeat Intramuscular Bolus Injections in Healthy Adult Subjects. Burdick, M; Dupuis, M; Gartner, M; Grenier, J; Hurliman, M; Mamelok, R; Noymer, P; Sheldon, C; Xie, Y, 2017)	2.17
"Ketorolac tromethamine is a potent nonsteroidal anti-inflammatory drug that is widely used in the treatment of moderate to severe pain. "	( Development and validation of a high-performance thin-layer chromatographic method, with densitometry, for quantitative analysis of ketorolac tromethamine in human plasma. Castañeda-Hernández, G; González-de la Parra, M; López-Bojórquez, E; Namur, S, )	1.78
"Ketorolac tromethamine (KT) is a non-steroidal anti-inflammatory drug that belongs to the class of heteroaryl acetic acid derivatives. "	( Ketorolac tromethamine formulations: an overview. Kumar, RV; Singh, G; Sinha, VR, 2009)	3.24
"Ketorolac tromethamine is a potent analgesic and moderately effective anti-inflammatory drug approved for treatment of moderately severe acute pain as an intravenous/intramuscular injectable solution and an oral tablet. "	( A novel formulation of ketorolac tromethamine for intranasal administration: preclinical safety evaluation. Boyer, KC; McDonald, P; Zoetis, T, )	1.88
"Ketorolac tromethamine is a racemic, non-steroidal, anti-inflammatory drug (NSAID). "	( Pulmonary and nasal deposition of ketorolac tromethamine solution (SPRIX) following intranasal administration. Bacon, R; Newman, S; Pitcairn, G; Rankin, L; Whiting, R, 2012)	2.1
"Ketorolac tromethamine (ketorolac) is a nonsedating drug with potent analgesic and moderate anti-inflammatory activity, which does not increase the sedation level. "	( Intracranial hemorrhage requiring surgery in neurosurgical patients given ketorolac: a case-control study within a cohort (2001-2010). Abeni, D; Hernandez, H; La Rosa, I; Magni, G; Melillo, G; Rosa, G, 2013)	1.83
"Ketorolac tromethamine is an effective nonnarcotic choice for postoperative pain control following vitreoretinal surgery. "	( Intraoperative ketorolac and eye pain after viteoretinal surgery: a prospective, randomized, placebo-controlled study. Campochiaro, PA; de Juan, E; Elsing, SH; Fekrat, S; Haller, JA; Marsh, MJ; Raja, SC, 2003)	1.76
"Ketorolac Tromethamine (ketorolac) is a nonsteroidal anti-inflammatory drug (NSAID) with proven efficacy in decreasing postoperative pain in various surgical settings, including the treatment of spine deformities. "	( Use of ketorolac tromethamine in children undergoing scoliosis surgery. an analysis of complications. Bauer, RM; Choe, JC; Hwang, MW; Hyman, JE; Lee, FY; Roye, DP; Vitale, MG, )	2.03
"Ketorolac tromethamine is a nonsteroidal agent with potent analgesic and moderate antiinflammatory activity. "	( Effect of freezing, long-term storage, and microwave thawing on the stability of ketorolac tromethamine. Boitquin, LP; Galanti, LM; Hecq, JD; Jamart, J; Vanbeckbergen, DF, 2005)	2
"Ketorolac tromethamine 0.4% is a versatile agent and is effective when used as either monotherapy or as an adjunct therapy to steroids."	( An update on the use of ophthalmic ketorolac tromethamine 0.4%. Donnenfeld, ED; Perry, HD, 2006)	1.33
"Ketorolac tromethamine is a recent injectable non-steroidal anti-inflammatory drug (NSAID) with analgesic properties approved for short-term pain management. "	( Biphasic anaphylactic reaction to Ketorolac tromethamine. Bernardini, R; Bonini, M; Calogero, C; De Martino, M; Mori, F; Neri, P; Novembre, E; Pucci, N; Vierucci, A, )	1.85
"Ketorolac tromethamine is a relatively new non-steroidal anti-inflammatory drug (NSAID), with potent analgesic activity. "	( Renal hemodynamic effects of chronic ketorolac tromethamine treatment in aged lean and obese Zucker rats. Alavi, FK; Hoff, KK; Zawada, ET, 1995)	2.01
"Ketorolac tromethamine (KT) is a potent analgesic, most often used in its injectable form postoperatively. "	( Effects of ketorolac tromethamine on erythropoietin levels in Sprague Dawley rats. Alavi, FK; Hoff, KK; Leyse, JW; Santella, RN; Zawada, ET, 1994)	2.12
"Ketorolac tromethamine is a newly available non-steroidal anti-inflammatory drug which is suitable for parenteral administration. "	( Use of ketorolac by continuous subcutaneous infusion for the control of cancer-related pain. Myers, KG; Trotman, IF, 1994)	1.73
"Ketorolac tromethamine (Toradol) is a nonsteroidal antiinflammatory drug (NSAID) available in intramuscular (IM) and oral formulations for the management of acute pain. "	( The use of ketorolac in the management of postoperative pain. Burchmore, M; Bynum, L; DeAndrade, JR; Maneatis, T; Maslanka, M, 1994)	1.73
"Ketorolac tromethamine (KT) is a new non-narcotic parenteral analgesic which lacks the respiratory depressant and hypotensive side effects of narcotics. "	( Lack of efficacy of ketorolac tromethamine for analgesia on patients undergoing colonoscopy. Deal, SE; Heuman, DM; Pandak, WM, 1993)	2.05
"Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug with potent analgesic properties. "	( Gastrointestinal complications associated with intramuscular ketorolac tromethamine therapy in the elderly. Elboim, CM; Maliekal, J, )	1.82
"Ketorolac tromethamine is a nonsteroidal anti-inflammatory agent that inhibits the activity of cyclooxygenase, one of the two major enzymes responsible for the conversion of arachidonic acid to inflammatory substances."	( Results of a survey of patients with ocular allergy treated with topical ketorolac tromethamine. Raizman, MB, )	1.08
"Ketorolac tromethamine (Toradol) is a parenteral, nonsteroidal antiinflammatory drug that is being extensively used to provide postoperative analgesia. "	( Intraoperative ketorolac has an opioid-sparing effect in women after diagnostic laparoscopy but not after laparoscopic tubal ligation. Green, CR; Kothary, SP; Levy, L; Pandit, SK; Schork, MA; Tait, AR, 1996)	1.74
"Ketorolac tromethamine (KT) is a nonsteroidal, antiinflammatory analgesic. "	( Ketorolac tromethamine and hemorrhage in tonsillectomy: a prospective, randomized, double-blind study. Bailey, R; Burgess, LP; Sinha, C, 1997)	3.18
"Ketorolac tromethamine (KT) is a non-steroidal drug with potent analgesic and anti-inflammatory activity and is absorbed rapidly (Tmax < 1.0 h) with an efficiency > 87% following oral and intramuscular administration. "	( Microencapsulation of ketorolac tromethamine by means of a coacervation-phase separation technique induced by the addition of non-solvent. Demirel, M; Genç, L; Güler, E; Hegazy, N, )	1.89
"Ketorolac tromethamine (Toradol) is a relatively new, potent, non-narcotic analgesic with cyclooxygenase (COX) inhibitory activity and has been associated with gastric and renal toxicity in people and dogs. "	( Plasma prostaglandin E2 concentrations after single dose administration of ketorolac tromethamine (Toradol) in dogs. Burger, J; Conlon, P; Pasloske, K, 1998)	1.97
"Ketorolac tromethamine is a potent non-narcotic analgesic with moderate anti-inflammatory activity. "	( Development and evaluation of nasal formulations of ketorolac. Needham, TE; Quadir, M; Zia, H, )	1.57
"Ketorolac tromethamine is a new injectable/oral nonsteroidal anti-inflammatory analgesic with no apparent opiate receptor activity that has been administered alone and in combination with other opiate analgesics for the treatment of postoperative pain. "	( Ketorolac tromethamine: an oral/injectable nonsteroidal anti-inflammatory for postoperative pain control. Redden, RJ, 1992)	3.17
"Ketorolac tromethamine is a highly potent member of a class of compounds having both analgesic and antiinflammatory activity. "	( The pharmacologic activity of ketorolac tromethamine. Rooks, WH, 1990)	2.01
"Ketorolac tromethamine is a potent prostaglandin synthetase inhibitor useful in the treatment of postoperative pain. "	( Effects of ketorolac tromethamine on hemostasis. Greer, IA, 1990)	2.11
"Ketorolac tromethamine is a pyrrolo-pyrrole nonsteroidal antiinflammatory drug (NSAID) with potent analgesic effects when administered intramuscularly for the treatment of acute pain. "	( Ketorolac: a parenteral nonsteroidal antiinflammatory drug. Resman-Targoff, BH, 1990)	1.72
"Ketorolac tromethamine is a nonsteroidal, analgesic, anti-inflammatory, antipyretic investigational drug with anti-prostaglandin synthetase activity."	( Pharmacokinetics of single-dose oral and intramuscular ketorolac tromethamine in the young and elderly. Garg, DC; Jallad, NS; Martinez, JJ; Mroszczak, EJ; Weidler, DJ, 1990)	1.25
"Ketorolac tromethamine is an effective nonsteroidal anti-inflammatory agent that may be a useful substitute for corticosteroids following ocular surgery."	( Effect of ketorolac on herpes simplex virus type one ocular infection in rabbits. Fraser-Smith, EB; Matthews, TR, 1988)	1
"Ketorolac tromethamine is a new non-steroidal compound being considered as an anti-inflammatory ophthalmic drug."	( Effect of ketorolac on Pseudomonas aeruginosa ocular infection in rabbits. Fraser-Smith, EB; Matthews, TR, 1988)	1
"Ketorolac tromethamine is a new injectable nonnarcotic analgesic. "	( Comparison of intramuscular ketorolac tromethamine and morphine sulfate for analgesia of pain after major surgery. Allbon, C; Brown, CR; Koshiver, JE; Yee, JP, )	1.87

Excerpt	Reference	Relevance
"Ketorolac tromethamine has to be given every 6 hr intramuscularly in patients for acute pain, so to avoid frequent dosing and patient inconvenience we found it to be a suitable candidate for parenteral controlled delivery by biodegradable microspheres for the present study. "	( Formulation, characterization, and evaluation of ketorolac tromethamine-loaded biodegradable microspheres. Sinha, VR; Trehan, A, )	1.83
"Ketorolac Tromethamine has proven efficacy in decreasing postoperative pain but there is concern with postoperative epidural bleeding after spine procedures."	( Bleeding risk with ketorolac after lumbar microdiscectomy. Chin, KR; Marcotte, P; Sundram, H, 2007)	1.06
"Ketorolac tromethamine has been singled out as an NSAID with a distinct gastrotoxicity profile."	( Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Agostinis, L; Cattaruzzi, C; García Rodríguez, LA; Troncon, MG, 1998)	1.02
"Ketorolac tromethamine has been used for the symptomatic relief of moderate to severe postoperative pain, including that associated with abdominal, gynecologic, oral, orthopedic, or urologic surgery."	( Ketorolac, an injectable nonnarcotic analgesic. Litvak, KM; McEvoy, GK, 1990)	1

Excerpt	Reference	Relevance
"Ketorolac tromethamine-treated patients reported a total of 62 adverse events (17 considered drug-related) and the paracetamol/codeine-treated patients reported 65 (20 considered drug-related); the adverse event profiles of the two treatment regimens were similar."	( Comparative study of ketorolac and paracetamol/codeine in alleviating pain following gynaecological surgery. Doessland, S; Lindbaek, E; Vangen, O, )	0.85

Excerpt	Reference	Relevance
" Significantly fewer patients treated with ketorolac reported adverse events in comparison with those treated with meperidine (17% and 59%, respectively), which suggests that it possesses a better therapeutic index than meperidine."	( Comparison of the efficacy and safety of ketorolac and meperidine in the relief of dental pain. Angelocci, D; Bynum, L; Fox, K; Fricke, JR; McHugh, D; Yee, JP, 1992)	0.28
" Ketorolac was well tolerated, with rates of adverse events generally lower than those of the opiate comparators."	( Analgesic efficacy and safety of single-dose oral and intramuscular ketorolac tromethamine for postoperative pain. Brown, CR; Bynum, LJ; Clarke, PJ; Dickie, G; Evans, SA; Moodie, JE; Smith, BA; Wild, VM, 1990)	0.51
" Three patients (one on ketorolac, two on Doleron) withdrew because of adverse events (vomiting)."	( Analgesic efficacy and safety comparison of ketorolac tromethamine and Doleron for the alleviation of orthopaedic post-operative pain. Johansson, S; Josefsson, G; Lindstrand, A; Malstam, J; Stenstroem, A, )	0.39
" The safety profile was also studied by recording all adverse events noted."	( Single-blind comparative analgesic and safety study of single doses of intramuscularly administered ketorolac tromethamine and pethidine hydrochloride in patients with pain following orthopaedic surgery. Chhatwal, V; Kumar, VP; Lai, FO; Pereira, BP; Satku, K, 1994)	0.5
"The end points analyzed were adverse effects, duration of postoperative ileus, degree of pain control, length of hospitalization, and development of postoperative confusion as measured on serial MMSEs."	( Does patient-controlled analgesia achieve better control of pain and fewer adverse effects than intramuscular analgesia? A prospective randomized trial. Avecilla, CS; Berg, RL; Nitschke, LF; Schlösser, CT; Selthafner, JV; Wengert, TJ, 1996)	0.29
"Only two patients, both in the PCA group, reported adverse effects; neither required a change in analgesia group."	( Does patient-controlled analgesia achieve better control of pain and fewer adverse effects than intramuscular analgesia? A prospective randomized trial. Avecilla, CS; Berg, RL; Nitschke, LF; Schlösser, CT; Selthafner, JV; Wengert, TJ, 1996)	0.29
" Most patients should probably be managed with PCA narcotics, but the addition of ketorolac might reduce narcotic dose and resultant adverse effects."	( Does patient-controlled analgesia achieve better control of pain and fewer adverse effects than intramuscular analgesia? A prospective randomized trial. Avecilla, CS; Berg, RL; Nitschke, LF; Schlösser, CT; Selthafner, JV; Wengert, TJ, 1996)	0.29
"Levels of sedation, pain intensity, pain relief, and adverse events were recorded at baseline, at 2, 4, and 6 hours, and at termination."	( Evaluation of the safety and efficacy of ketorolac versus morphine by patient-controlled analgesia for postoperative pain. Bynum, L; Fanciullo, G; Hubbard, L; Maneatis, T; O'Hara, DA; Seuffert, P; Shefrin, A, )	0.13
" No treatment-related adverse events were reported in the ketorolac group, and only one treatment-related adverse event was reported in the vehicle group."	( Analgesic efficacy and safety of nonpreserved ketorolac tromethamine ophthalmic solution following radial keratotomy. Ketorolac Radial Keratotomy Study Group. Yee, RW, 1998)	0.56
"5% ophthalmic solution was significantly more effective than, and as safe as, vehicle in the treatment of postoperative pain associated with radial keratotomy."	( Analgesic efficacy and safety of nonpreserved ketorolac tromethamine ophthalmic solution following radial keratotomy. Ketorolac Radial Keratotomy Study Group. Yee, RW, 1998)	0.56
" Patients treated with ketorolac experienced the same low rate of treatment-related adverse events as those treated with the vehicle and exhibited the same improvement in visual acuity and manifest refraction."	( Efficacy and safety of nonpreserved ketorolac ophthalmic solution in postoperative ocular pain following radial keratotomy. Abel, ML; Brint, SF; Cheetham, JK; DeGryse, R; Rosenthal, A; Thompson, VM, 1999)	0.3
"5% ophthalmic solution was significantly more effective than, and as safe as, the vehicle in alleviating the postoperative pain associated with RK."	( Efficacy and safety of nonpreserved ketorolac ophthalmic solution in postoperative ocular pain following radial keratotomy. Abel, ML; Brint, SF; Cheetham, JK; DeGryse, R; Rosenthal, A; Thompson, VM, 1999)	0.3
" No adverse events were reported, and there were no significant changes in intraocular pressure in either group."	( Comparison of the efficacy and safety of ketorolac tromethamine 0.5% and prednisolone acetate 1% after cataract surgery. Jenkins, JE; Pendelton, RA; Simone, JN, 1999)	0.57
" Adverse symptoms were acceptable with both drugs."	( A double-blind evaluation of the analgesic efficacy and toxicity of oral ketorolac and diclofenac in cancer pain. The TD/10 recordati Protocol Study Group. Camaggi, CM; Pannuti, F; Robustelli della Cuna, G; Strocchi, E; Ventaffrida, V, )	0.13
" To ensure participant safety, biomicroscopy, ophthalmoscopy, intraocular pressure, adverse events, and preoperative and postoperative visual acuity and refractive error were also monitored."	( Efficacy and safety profile of ketorolac 0.5% ophthalmic solution in the prevention of surgically induced miosis during cataract surgery. Cheetham, JK; Grosserode, R; Rosenthal, A; Stewart, R, 1999)	0.3
" Few adverse events were reported with ketorolac treatment (less than with vehicle), and there were no clinically significant changes in any of the safety variables monitored."	( Analgesic efficacy and safety of ketorolac after photorefractive keratectomy. Ketorolac Study Group. Cooperman, BB; Rajpal, RK, )	0.13
"5% ophthalmic solution (Acular) is safe and significantly more effective than vehicle in alleviating pain following photorefractive keratectomy."	( Analgesic efficacy and safety of ketorolac after photorefractive keratectomy. Ketorolac Study Group. Cooperman, BB; Rajpal, RK, )	0.13
"5% ophthalmic solution instilled four times daily is effective and safe in reducing the signs and symptoms of seasonal allergic conjunctivitis."	( Efficacy and safety of ketorolac tromethamine 0.5% and levocabastine 0.05%: a multicenter comparison in patients with seasonal allergic conjunctivitis. Donshik, PC; Pearlman, D; Pinnas, J; Raizman, MB; Tauber, J; Tinkelman, D; Walters, TR, )	0.44
"To evaluate whether topical ketorolac tromethamine can reduce the adverse effect of laser in situ keratomileusis (LASIK)."	( Topical ketorolac tromethamine in the reduction of adverse effects of laser in situ keratomileusist. Kosrirukvongs, P; Pornpanich, K; Prabhasawat, P; Srivannaboon, S, 2001)	1.04
"Ketorolac is a safe and effective supplement to opioid based analgesia for pain control after partial nephrectomy."	( Ketorolac: safe and effective analgesia for the management of renal cortical tumors with partial nephrectomy. Diblasio, CJ; Kattan, MW; Russo, P; Snyder, ME, 2004)	0.32
" Adverse events, epithelial healing, and visual acuity were recorded."	( Safety and efficacy of ketorolac tromethamine 0.4% ophthalmic solution in post-photorefractive keratectomy patients. Cheetham, JK; Donnenfeld, ED; Raizman, M; Sandoval, HP; Schiffman, R; Solomon, KD; Stern, K; VanDenburgh, A, 2004)	0.63
"4% ophthalmic solution is safe and effective in reducing ocular pain when used 4 times daily for up to 4 days post PRK."	( Safety and efficacy of ketorolac tromethamine 0.4% ophthalmic solution in post-photorefractive keratectomy patients. Cheetham, JK; Donnenfeld, ED; Raizman, M; Sandoval, HP; Schiffman, R; Solomon, KD; Stern, K; VanDenburgh, A, 2004)	0.63
" The primary outcome measure was reduction in ureteral stent symptoms, and the secondary outcome measure was the safety of intravesical instillation of each agent through assessment of drug-related adverse events."	( Double-blind randomized controlled trial assessing the safety and efficacy of intravesical agents for ureteral stent symptoms after extracorporeal shockwave lithotripsy. Beiko, DT; Brock, GB; Denstedt, JD; Knudsen, BE; Nott, L; Pautler, SE; Razvi, H; Watterson, JD, 2004)	0.32
" From our results, ketorolac appears to be the most effective intravesical agent in reducing stent-related patient discomfort, and we have established that intravesical instillation of ketorolac is safe in humans."	( Double-blind randomized controlled trial assessing the safety and efficacy of intravesical agents for ureteral stent symptoms after extracorporeal shockwave lithotripsy. Beiko, DT; Brock, GB; Denstedt, JD; Knudsen, BE; Nott, L; Pautler, SE; Razvi, H; Watterson, JD, 2004)	0.32
" Safety assessment showed no adverse effects on renal or hepatic function tests, surgical drain output, or continuous oximetry between placebo and ketorolac groups."	( Postoperative ketorolac tromethamine use in infants aged 6-18 months: the effect on morphine usage, safety assessment, and stereo-specific pharmacokinetics. Anderson, GD; Bradford, H; Chen, J; Ellenbogen, RG; Kantor, ED; Lynn, AM; Salinger, DH; Seng, KY; Vicini, P, 2007)	0.7
" No adverse effects on surgical drain output, oximetry measured saturations, renal or hepatic function tests were seen."	( Postoperative ketorolac tromethamine use in infants aged 6-18 months: the effect on morphine usage, safety assessment, and stereo-specific pharmacokinetics. Anderson, GD; Bradford, H; Chen, J; Ellenbogen, RG; Kantor, ED; Lynn, AM; Salinger, DH; Seng, KY; Vicini, P, 2007)	0.7
"Commercially available ketorolac tromethamine was found to be toxic to the retinas of albino rabbits following multiple intravitreal injections at a dose of 3 mg while no electrophysiologic toxicity was found."	( Retinal toxicity of commercially available intravitreal ketorolac in albino rabbits. Heilweil, G; Komarowska, I; Loewenstein, A; Perlman, I; Rosenfeld, PJ, 2009)	0.66
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."	( Developing structure-activity relationships for the prediction of hepatotoxicity. Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010)	0.36
" Local tolerance and systemic toxicology studies were performed in rats and rabbits and showed that intranasal administration of SPRIX exhibits toxicity similar to that of other routes of administration and does not result in any adverse effects on the nasal passage and upper and lower respiratory system."	( A novel formulation of ketorolac tromethamine for intranasal administration: preclinical safety evaluation. Boyer, KC; McDonald, P; Zoetis, T, )	0.44
" No adverse reaction or undesirable gastrointestinal side effect was observed."	( Evaluation of novel adhesive film containing ketorolac for post-surgery pain control: a safety and efficacy study. Al-Askar, M; Al-Hezaimi, K; Alsarra, IA; Fu, JH; Selamhe, Z; Wang, HL, 2011)	0.37
" No serious adverse effects associated with bowel stimulation were reported."	( Safety and efficacy of immediate postoperative feeding and bowel stimulation to prevent ileus after major gynecologic surgical procedures. Fanning, J; Hojat, R, 2011)	0.37
"Immediate postoperative feeding and bowel stimulation is a safe and effective approach to preventing ileus in patients who undergo major gynecologic surgical procedures."	( Safety and efficacy of immediate postoperative feeding and bowel stimulation to prevent ileus after major gynecologic surgical procedures. Fanning, J; Hojat, R, 2011)	0.37
" The most frequently reported adverse events in both groups were associated with nasal discomfort."	( Intranasal ketorolac tromethamine (SPRIX(R)) containing 6% of lidocaine (ROX-828) for acute treatment of migraine: safety and efficacy data from a phase II clinical trial. Bregman, D; Färkkila, M; Fenzl, E; Pfaffenrath, V, 2012)	0.77

Excerpt	Reference	Relevance
" The absorption of ketorolac is rapid, Cmax being attained between 20 to 60 min."	( Clinical pharmacokinetics of ketorolac tromethamine. Brocks, DR; Jamali, F, 1992)	0.57
" Values of steady-state volume of distribution and plasma clearance were approximately two times higher than those in adults but values of elimination half-life were similar."	( The pharmacokinetics of postoperative intravenous ketorolac tromethamine in children. Maunuksela, EL; Olkkola, KT, 1991)	0.53
" The elimination of ketorolac was decreased slightly in the elderly following both doses, as evidenced by a prolongation in half-life (4."	( Pharmacokinetics of single-dose oral and intramuscular ketorolac tromethamine in the young and elderly. Garg, DC; Jallad, NS; Martinez, JJ; Mroszczak, EJ; Weidler, DJ, 1990)	0.53
" The rate of absorption of K and formation of PHK, as determined by Cmax and Tmax values, was significantly slower following the im doses."	( Pharmacokinetics of ketorolac and p-hydroxyketorolac following oral and intramuscular administration of ketorolac tromethamine. Bynum, L; Jung, D; Ling, TL; Mroszczak, EJ; Sevelius, H; Wu, A, 1989)	0.49
"The relationship between the pharmacokinetic properties and the analgesic effect of ketorolac was evaluated with the pain-induced functional impairment model in the rat."	( Relationship between pharmacokinetics and the analgesic effect of ketorolac in the rat. Flores-Murrieta, FJ; Granados-Soto, V; Hong, E; López-Muñoz, FJ, 1995)	0.29
" Pharmacokinetic parameters were derived from plasma samples collected after the first and last active doses."	( Tolerability, central effects and pharmacokinetics of intravenous ketorolac tromethamine in volunteers. Bullingham, R; Hooftman, L; Lloyd, J; Lucker, P; Mroszczak, E, 1994)	0.53
"Previous pharmacokinetic studies on racemic ketorolac using nonstereoselective analytical methods have indicated that the plasma clearance of ketorolac is higher and the volume of distribution greater in children than in adults."	( Stereoselective pharmacokinetics of ketorolac in children, adolescents and adults. Bullingham, RE; Hamunen, K; Maunuksela, EL; Olkkola, KT; Sarvela, J, 1999)	0.3
" Clearance (CL), volume of distribution at steady state (Vss) and elimination (Vz) and elimination half-life (t1/2,z) were calculated with standard methods."	( Stereoselective pharmacokinetics of ketorolac in children, adolescents and adults. Bullingham, RE; Hamunen, K; Maunuksela, EL; Olkkola, KT; Sarvela, J, 1999)	0.3
"On a pharmacokinetic basis, the maintenance dose requirements of ketorolac are similar in children, adolescents and adults."	( Stereoselective pharmacokinetics of ketorolac in children, adolescents and adults. Bullingham, RE; Hamunen, K; Maunuksela, EL; Olkkola, KT; Sarvela, J, 1999)	0.3
" Individual concentration-versus-time relationships were best fit to a two-compartment pharmacokinetic model by using SAAM II."	( Age-stratified pharmacokinetics of ketorolac tromethamine in pediatric surgical patients. Avram, MJ; Birmingham, PK; Coté, CJ; Dsida, RM; Heffner, CL; Wang, Z; Wheeler, M, 2002)	0.59
" Body weight-normalized two-compartment pharmacokinetic variables did not differ among pediatric patients <17 yr old and were similar to adult values."	( Age-stratified pharmacokinetics of ketorolac tromethamine in pediatric surgical patients. Avram, MJ; Birmingham, PK; Coté, CJ; Dsida, RM; Heffner, CL; Wang, Z; Wheeler, M, 2002)	0.59
" Inclusion of covariates did not significantly decrease the nonlinear mixed-effects model objective function values and between-subject variability in the pharmacokinetic parameters of nested models."	( Postoperative ketorolac tromethamine use in infants aged 6-18 months: the effect on morphine usage, safety assessment, and stereo-specific pharmacokinetics. Anderson, GD; Bradford, H; Chen, J; Ellenbogen, RG; Kantor, ED; Lynn, AM; Salinger, DH; Seng, KY; Vicini, P, 2007)	0.7
" The pharmacokinetic characteristics of intranasal ketorolac tromethamine in children have not been characterized."	( The pharmacokinetics of ketorolac after single postoperative intranasal administration in adolescent patients. Anderson, BJ; Drover, DR; Hammer, GB, 2012)	0.63
" A similar pharmacokinetic study was repeated in a subgroup of these women 4-5 months after delivery (late postpartum, Group LP) and in a group of unrelated, healthy non-pregnant female volunteers (controls, Group C)."	( Pharmacokinetics of intravenous ketorolac following caesarean delivery. Allegaert, K; de Hoon, J; Deprest, J; Kulo, A; Smits, A; van Calsteren, K; van de Velde, M; Verbesselt, R, 2012)	0.38
" No significant covariates of pharmacokinetic estimates, including gestational age, preterm vs."	( Pharmacokinetics of intravenous ketorolac following caesarean delivery. Allegaert, K; de Hoon, J; Deprest, J; Kulo, A; Smits, A; van Calsteren, K; van de Velde, M; Verbesselt, R, 2012)	0.38
" These data provide pharmacokinetic estimates on which to base studies on post caesarean analgesia."	( Pharmacokinetics of intravenous ketorolac following caesarean delivery. Allegaert, K; de Hoon, J; Deprest, J; Kulo, A; Smits, A; van Calsteren, K; van de Velde, M; Verbesselt, R, 2012)	0.38
" The elimination half-life (t1/2) in group B (3."	( Pharmacokinetic comparison of ketorolac after intracameral, intravitreal, and suprachoroidal administration in rabbits. Cheng, H; Liu, S; Liu, W; Liu, Y; Lu, Q; Wang, M; Xue, M; Yue, Y; Zeng, H, )	0.13
"The nonsteroidal anti-inflammatory drug (NSAID) ketorolac tromethamine shows higher plasma concentrations and a longer plasma half-life in adults ≥65 years of age than in subjects aged <65 years, after intramuscular administration."	( Comparison of intranasal ketorolac tromethamine pharmacokinetics in younger and older adults. Bullingham, R; Juan, A, 2012)	0.94
"9 ng/mL) and mean (±SD) terminal elimination half-life (t(½β)) was 37 % longer (4."	( Comparison of intranasal ketorolac tromethamine pharmacokinetics in younger and older adults. Bullingham, R; Juan, A, 2012)	0.68
" To prove these results, in vivo pharmacokinetic studies in human volunteers were designed to study the in vitro-in vivo correlation."	( Development, evaluation and pharmacokinetics of time-dependent ketorolac tromethamine tablets. Veerareddy, PR; Vemula, SK, 2013)	0.63
" From the pharmacokinetic evaluation, the immediate-release tablets producing peak plasma concentration (C(max)) was 4482."	( Development, evaluation and pharmacokinetics of time-dependent ketorolac tromethamine tablets. Veerareddy, PR; Vemula, SK, 2013)	0.63
" Despite these differences, even commonly administered drugs have not undergone pharmacokinetic evaluation in pregnant women or at delivery."	( Paracetamol and ketorolac pharmacokinetics and metabolism at delivery and during postpartum. Allegaert, K; Hendrickx, S; Kelchtermans, J; Kulo, A; Smits, A; van Calsteren, K; van de Velde, M, 2012)	0.38
" From the in vivo pharmacokinetic evaluation, the optimized formulation showed peak plasma concentration (Cmax) as 1 248."	( Formulation and pharmacokinetics of ketorolac tromethamine fast dissolving tablets. Mettu, SR; Veerareddy, PR, 2013)	0.66
" From the pharmacokinetic evaluation, the immediate release core mini-tablets reached peak plasma concentration (Cmax of 4532."	( Formulation and pharmacokinetics of colon-specific double-compression coated mini-tablets: Chronopharmaceutical delivery of ketorolac tromethamine. Vemula, SK, 2015)	0.62
" The purpose of this study was to determine the pharmacokinetic profile of KT in horses after intravenous (i."	( Pharmacokinetics of ketorolac tromethamine in horses after intravenous, intramuscular, and oral single-dose administration. Bianco, AW; Constable, PD; Cooper, BR; Taylor, SD, 2016)	0.76
" The pharmacokinetic and safety profiles were evaluated for both treatments."	( Comparison of the Pharmacokinetics of Ketorolac Tromethamine After Continuous Subcutaneous Infusion and Repeat Intramuscular Bolus Injections in Healthy Adult Subjects. Burdick, M; Dupuis, M; Gartner, M; Grenier, J; Hurliman, M; Mamelok, R; Noymer, P; Sheldon, C; Xie, Y, 2017)	0.73
" Finally, the simultaneous increase in CL and Vss resulted in similar estimates for elimination half-life in both unpaired and paired analysis."	( Enantiomer-specific ketorolac pharmacokinetics in young women, including pregnancy and postpartum period. Allegaert, K; De Hoon, J; Deprest, J; Kulo, A; Maleškić, S; Smits, A; Van Calsteren, K; Van de Velde, M; Verbesselt, R, 2017)	0.46

Excerpt	Reference	Relevance
"We evaluate the safety and efficacy of a single dose of hyoscyamine sulfate in combination with ketorolac tromethamine for the reduction of pain in emergency department patients with ureteral colic."	( Sublingual hyoscyamine sulfate in combination with ketorolac tromethamine for ureteral colic: a randomized, double-blind, controlled trial. Brizendine, EJ; Cordell, WH; Giles, BK; Jones, JB, 2001)	0.78
"Hyoscyamine sulfate did not provide any additional pain relief from ureteral colic when administered with ketorolac tromethamine."	( Sublingual hyoscyamine sulfate in combination with ketorolac tromethamine for ureteral colic: a randomized, double-blind, controlled trial. Brizendine, EJ; Cordell, WH; Giles, BK; Jones, JB, 2001)	0.78
"To observe the effect of Ketorolac tromethamine combined with dezocine prior administration on hemodynamics and postoperative sedation in patients undergoing laparoscopic hernia repair."	( Effect of ketorolac tromethamine combined with dezocine prior administration on hemodynamics and postoperative analgesia in patients undergoing laparoscopic hernia repair. Cai, Z; Fu, B; Kang, Y; Li, Y; Wang, J; Wu, Y, 2022)	1.43
"100 male patients aged 60 to 80 years old, a line to elective laparoscopic inguinal hernia repair, were randomly divided into four groups: control group (Group A) and dezocine group (Group B), ketorolac tromethamine group (Group C), ketorolac tromethamine combined with dezocine group (Group D)."	( Effect of ketorolac tromethamine combined with dezocine prior administration on hemodynamics and postoperative analgesia in patients undergoing laparoscopic hernia repair. Cai, Z; Fu, B; Kang, Y; Li, Y; Wang, J; Wu, Y, 2022)	1.31
"To observe the effect of ketorolac tromethamine combined with remifentanil in sedation and analgesia during general anesthesia emergence and reducing general anesthesia complications."	( Effect of Ketorolac Tromethamine Combined With Remifentanil on Reducing Complications During the General Anesthesia Emergence. Cao, H; Chang, J; Ran, R; Wang, Y; Xiao, Y; Zhang, X, 2023)	1.62
" Routine general anesthesia combined with endotracheal intubation was given for general anesthesia, and different treatments were administered when the skin was sutured."	( Effect of Ketorolac Tromethamine Combined With Remifentanil on Reducing Complications During the General Anesthesia Emergence. Cao, H; Chang, J; Ran, R; Wang, Y; Xiao, Y; Zhang, X, 2023)	1.31
"Ketorolac tromethamine combined with remifentanil can effectively relieve pain and sedation during general anesthesia recovery and reduce the incidence of complications related to general anesthesia recovery."	( Effect of Ketorolac Tromethamine Combined With Remifentanil on Reducing Complications During the General Anesthesia Emergence. Cao, H; Chang, J; Ran, R; Wang, Y; Xiao, Y; Zhang, X, 2023)	2.76

Excerpt	Reference	Relevance
" Its oral bioavailability is estimated to range from 80 to 100%."	( Clinical pharmacokinetics of ketorolac tromethamine. Brocks, DR; Jamali, F, 1992)	0.57
" Ketorolac is well absorbed and has a rapid onset of action."	( Ketorolac: a parenteral nonsteroidal antiinflammatory drug. Resman-Targoff, BH, 1990)	0.28
" The rate of absorption of K and formation of PHK, as determined by Cmax and Tmax values, was significantly slower following the im doses."	( Pharmacokinetics of ketorolac and p-hydroxyketorolac following oral and intramuscular administration of ketorolac tromethamine. Bynum, L; Jung, D; Ling, TL; Mroszczak, EJ; Sevelius, H; Wu, A, 1989)	0.49
"9 h, respectively) and the systemic bioavailability was essentially complete."	( Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration. Bynum, L; Jung, D; Mroszczak, E, 1988)	0.6
"The bioavailability of ketorolac after administration of two oral formulations containing 10 mg of ketorolac tromethamine, Exodol and Dolac, to 12 healthy Mexican volunteers was compared."	( Comparative bioavailability of two oral formulations of ketorolac tromethamine: Dolac and Exodol. Castañeda-Hernández, G; Flores-Murrieta, FJ; Granados-Soto, V; Herrera, JE; Hong, E, 1994)	0.75
" Ketorolac applied in this way had a bioavailability greater than 80%."	( Nasal formulations of ketorolac tromethamine: technological evaluation--bioavailability and tolerability in rabbits. Bottoni, G; Canali, S; Peano, S; Rivolta, R; Santus, G; Testa, B, 1993)	0.6
"This study was designed to examine the effect of benzalkonium chloride/ethylenediaminetetraacetic acid (BAK/EDTA) on the ocular bioavailability (Focular) of ketorolac tromethamine after ocular instillation to normal and de-epithelialized corneas of rabbits both in vitro and in vivo."	( Effect of benzalkonium chloride/EDTA on the ocular bioavailability of ketorolac tromethamine following ocular instillation to normal and de-epithelialized corneas of rabbits. Madhu, C; Nguyen, TG; Rix, PJ; Shackleton, MJ; Tang-Liu, DD, 1996)	0.73
" Its oral bioavailability is estimated to be 80%."	( Microencapsulation of ketorolac tromethamine by means of a coacervation-phase separation technique induced by the addition of non-solvent. Demirel, M; Genç, L; Güler, E; Hegazy, N, )	0.45
" A nasal spray formulation of ketorolac tromethamine showed the highest absorption with an absolute bioavailability of 91%."	( Development and evaluation of nasal formulations of ketorolac. Needham, TE; Quadir, M; Zia, H, )	0.42
" However, a literature search did not identify published data concerning the bioavailability of these formulations in the Mexican population."	( Bioavailability of two sublingual formulations of ketorolac tromethamine 30 mg: a randomized, open-label, single-dose, two-period crossover comparison in healthy Mexican adult volunteers. Burke-Fraga, V; de Lago, A; Galán-Herrera, JF; González-de la Parra, M; Jiménez, P; López-Bojórquez, E; Maya-Barrios, JA; Namur, S; Oliva, I; Poo, JL, 2008)	0.6
"The aim of this study was to compare the bioavailability of 2 sublingual formulations of ketorolac 30-mg tablets in healthy Mexican adult volunteers."	( Bioavailability of two sublingual formulations of ketorolac tromethamine 30 mg: a randomized, open-label, single-dose, two-period crossover comparison in healthy Mexican adult volunteers. Burke-Fraga, V; de Lago, A; Galán-Herrera, JF; González-de la Parra, M; Jiménez, P; López-Bojórquez, E; Maya-Barrios, JA; Namur, S; Oliva, I; Poo, JL, 2008)	0.6
"This was a randomized-sequence, open-label, single-dose, 2-period crossover (2 dosing periods x 2 treatments) study comparing the bioavailability of two 30-mg sublingual tablet formulations of ketorolac."	( Bioavailability of two sublingual formulations of ketorolac tromethamine 30 mg: a randomized, open-label, single-dose, two-period crossover comparison in healthy Mexican adult volunteers. Burke-Fraga, V; de Lago, A; Galán-Herrera, JF; González-de la Parra, M; Jiménez, P; López-Bojórquez, E; Maya-Barrios, JA; Namur, S; Oliva, I; Poo, JL, 2008)	0.6
"The poor bioavailability and therapeutic response exhibited by conventional ophthalmic solutions may be overcome by the use of thermo-reversible in situ gel."	( Effect of salts on gelation and drug release profiles of methylcellulose-based ophthalmic thermo-reversible in situ gels. Bain, MK; Bhowmik, M; Chattopadhyay, D; Ghosh, LK, 2011)	0.37
"The current study is intended to develop the fast dissolving tablets of Ketorolac tromethamine using different superdisintegrants to improve the dissolution rate and absorption rate to produce the bioavailability enhancement and rapid onset of action."	( Formulation and pharmacokinetics of ketorolac tromethamine fast dissolving tablets. Mettu, SR; Veerareddy, PR, 2013)	0.9
"In this, Ketorolac tromethamine fast dissolving tablets were prepared using different superdisintegrants and evaluated for different physical parameters, in vitro dissolution studies and in vivo pharmacokinetics to demonstrate the bioavailability enhancement."	( Formulation and pharmacokinetics of ketorolac tromethamine fast dissolving tablets. Mettu, SR; Veerareddy, PR, 2013)	1.08
"Hence the development of fast dissolving tablets using superdisintegrants was a good approach to improve the dissolution rate and absorption rate of Ketorolac tromethamine."	( Formulation and pharmacokinetics of ketorolac tromethamine fast dissolving tablets. Mettu, SR; Veerareddy, PR, 2013)	0.86
" Pharmacokinetic study of intranasal CPH containing 15% ketorolac tromethamine in rats demonstrated enhanced absolute bioavailability (68."	( Enhancement in bioavailability of ketorolac tromethamine via intranasal in situ hydrogel based on poloxamer 407 and carrageenan. Li, C; Li, Q; Liu, Y; Liu, Z; Lu, W; Yan, X, 2014)	0.93
" Relevant anti-inflammatory efficacy of KT-P407-HG revealed enough ability to provide sufficient bioavailability KT to reach easily the site of action."	( Developing Transdermal Applications of Ketorolac Tromethamine Entrapped in Stimuli Sensitive Block Copolymer Hydrogels. Alonso, C; Andrade, B; Calpena, AC; Clares, B; Coderch, L; Del Pozo, A; Fernández-Campos, F; Garduño-Ramírez, ML; Halbaut, L; Lane, ME; Mallandrich, M, 2017)	0.72
"There has been extensive utilization of poloxamer 407 (PM) for the delivery of various ophthalmic drugs aimed at efficient ophthalmic drug delivery approach for longer precorneal residence time along with acceptable bioavailability of drugs."	( Sustained release of ketorolac tromethamine from poloxamer 407/cellulose nanofibrils graft nanocollagen based ophthalmic formulations. Banerjee, R; Chattopadhyay, D; Das, D; Das, S; Dutta, K; Dutta, S; Ghosh, SK; Orasugh, JT; Pal, C; Zaman, A, 2019)	0.83
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" Through an in vitro test, we were able to evaluate the role that saliva plays in the bioavailability of the drug, observing that more than half of the applied dose is eliminated in an hour."	( HPV Lesions and Other Issues in the Oral Cavity Treatment and Removal without Pain. Calpena, AC; El Moussaoui, S; Fernández-Campos, F; Garrós, N; Mallandrich, M; Rodríguez Lagunas, MJ, 2021)	0.62
"Topical formulation of non-steroidal anti-inflammatory drugs (NSAIDs) exhibits many advantages over the oral administration route, such as avoiding the direct effect on GIT and avoiding the poor oral bioavailability of such drugs."	( Cyclodextrin/Adamantane-Grafted Polyethylene Glycol-Based Self-assembling Constructs for Topical Delivery of Ketorolac Tromethamine: Formulation, Characterization, and In Vivo Studies. Abdellatif, AAH; Almawash, S; El-Rasoul, SA; Mohammed, AM; Osman, SK; Safwat, MA; Zayed, G, 2022)	0.93

Excerpt	Relevance	Reference
"04) superior to diflunisal in reducing the pain severity during the first 9 h of treatment; a difference possibly related to the more flexible dosage regimen of ketorolac."	( Comparative multiple-dose study of ketorolac tromethamine and diflunisal for pain following orthopaedic surgery. Fernández-Sabaté, A; Portabella, F, )	0.41
" With the dosage regimens used, neither drug adequately controlled moderate to severe pain in the immediate postoperative period."	( Intravenous ketorolac tromethamine versus morphine sulfate in the treatment of immediate postoperative pain. Fragen, RJ; Peirce, RJ; Pemberton, DM, 1990)	0.66
" The present results show that the elderly may need slightly less frequent dosing of ketorolac than young adults to maintain similar plasma levels."	( Pharmacokinetics of single-dose oral and intramuscular ketorolac tromethamine in the young and elderly. Garg, DC; Jallad, NS; Martinez, JJ; Mroszczak, EJ; Weidler, DJ, 1990)	0.53
" Plasma and milk samples were collected on the two dosing days and on the first day after dosing."	( The excretion of ketorolac tromethamine into breast milk after multiple oral dosing. Bullingham, R; Lloyd, J; Manth, SM; Thompson, JS; Wischnik, A, 1989)	0.62
" Our results suggested a positive dose-response relationship for ketorolac."	( Ketorolac versus aspirin for postpartum uterine pain. Barden, TP; Bloomfield, SS; Cissell, GB; Mitchell, J; Yee, JP, )	0.13
" Treatment animals were then maintained on a regimen of intramuscular ketorolac using a three times a day dosing schedule for 14 days postoperatively."	( Ketorolac (Toradol) and acute random-pattern skin flap survival in rat. Cohen, JI; Cook, TA; Davis, RE; Robinson, JE; Urben, SL, 1995)	0.29
" To determine the effects of withdrawal all subjects were then given further dosing with placebo (4 times daily) for 2 days while maintaining the double-blind nature of the previous drug assignment."	( Tolerability, central effects and pharmacokinetics of intravenous ketorolac tromethamine in volunteers. Bullingham, R; Hooftman, L; Lloyd, J; Lucker, P; Mroszczak, E, 1994)	0.53
" The administered dosage was 10 mg every 6 h for ketorolac and 50 mg every 8 h for diclofenac sodium."	( Ketorolac versus diclofenac sodium in cancer pain. Corli, O; De Conno, F; Gallucci, M; Piva, L; Speranza, R; Tamburini, M; Toscani, F; Ventafridda, V, 1994)	0.29
"Randomized, double-blind, placebo-controlled, dose-response evaluation."	( Intravenous ketorolac as an adjunct to patient-controlled analgesia (PCA) for management of postgynecologic surgical pain. Paige, D; Sevarino, FB; Silverman, DG; Sinatra, RS, )	0.13
" In both tests KT had a poor analgesic effect without dose-response relationships."	( Ketorolac tromethamine: an experimental study of its analgesic effects in the rat. Bustamante, D; Paeile, C, 1993)	1.73
" A dose-response relationship was evident between average daily ketorolac dose and both gastrointestinal bleeding and operative site bleeding (trend test P < ."	( Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. A postmarketing surveillance study. Berlin, JA; Carson, JL; Feldman, H; Hennessy, S; Kimmel, S; Kinman, JL; Spitz, PW; Strom, BL, 1996)	0.29
" Topical dosing led to relatively low aqueous and undetectable vitreous levels."	( Intraocular penetration of periocular ketorolac and efficacy in experimental uveitis. Fiscella, RG; Rabiah, PK; Tessler, HH, 1996)	0.29
" In addition, the total daily dose of ketorolac was reduced following a change from intermittent bolus dosing to a continuous infusion."	( Prolonged central intravenous ketorolac continuous infusion in a cancer patient with intractable bone pain. Gordon, RL, 1998)	0.3
"Double-masked, multicenter, study of 200 patients dosed with 1 drop of study medication (ketorolac or vehicle) in the operated eye immediately after surgery (eye patched), with four-times daily dosing for the next 3 days starting 3 hours after surgery."	( Analgesic efficacy and safety of ketorolac after photorefractive keratectomy. Ketorolac Study Group. Cooperman, BB; Rajpal, RK, )	0.13
" Our data provide no evidence that children require either larger weight-adjusted doses or shorter dosing intervals than adults to provide similar plasma drug concentrations."	( Age-stratified pharmacokinetics of ketorolac tromethamine in pediatric surgical patients. Avram, MJ; Birmingham, PK; Coté, CJ; Dsida, RM; Heffner, CL; Wang, Z; Wheeler, M, 2002)	0.59
"Gelatin A microspheres (MS) of ketorolac tromethamine (KT) for intranasal systemic delivery were developed with the aim to avoid gastro-intestinal complications, to improve patient compliance, to use as an alternative therapy to conventional dosage forms, to achieve controlled blood level profiles, and to obtain improved therapeutic efficacy in the treatment of postoperative pain and migraine."	( Development and in vitro evaluations of gelatin A microspheres of ketorolac tromethamine for intranasal administration. Mishra, B; Sankar, C, 2003)	0.84
"Ketorolac tromethamine has to be given every 6 hr intramuscularly in patients for acute pain, so to avoid frequent dosing and patient inconvenience we found it to be a suitable candidate for parenteral controlled delivery by biodegradable microspheres for the present study."	( Formulation, characterization, and evaluation of ketorolac tromethamine-loaded biodegradable microspheres. Sinha, VR; Trehan, A, )	1.83
"5-fold longer than the traditional dosage form of ketorolac tromethamine."	( Novel depots of ketorolac esters have long-acting antinociceptive and antiinflammatory effects. Cheng, YL; Chia-Hui, H; Huang, KL; Liu, SY; Shieh, JP; Tzeng, JI; Wang, JJ, 2005)	0.58
"Maintenance of pupil size with 3-day ketorolac dosing was significantly better than with 1-day dosing (P<."	( Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic-response curve. Chou, T; Donnenfeld, ED; Nattis, A; Perry, HD; Solomon, R; Wittpenn, JR, 2006)	0.7
" Information on the pharmacokinetics of ketorolac in infants is sparse, making dosing difficult."	( Postoperative ketorolac tromethamine use in infants aged 6-18 months: the effect on morphine usage, safety assessment, and stereo-specific pharmacokinetics. Anderson, GD; Bradford, H; Chen, J; Ellenbogen, RG; Kantor, ED; Lynn, AM; Salinger, DH; Seng, KY; Vicini, P, 2007)	0.7
" Dosing simulations, using population pharmacokinetic parameters, showed no accumulation of S(-) ketorolac but steady increases in R(+) ketorolac."	( Postoperative ketorolac tromethamine use in infants aged 6-18 months: the effect on morphine usage, safety assessment, and stereo-specific pharmacokinetics. Anderson, GD; Bradford, H; Chen, J; Ellenbogen, RG; Kantor, ED; Lynn, AM; Salinger, DH; Seng, KY; Vicini, P, 2007)	0.7
" No interferences could be observed from the excipients commonly present in dosage forms."	( Spectrofluorometric determination of ketorolac tromethamine via its oxidation with cerium(IV) in pharmaceutical preparations and biological fluids. Aly, F; Eid, M; El-Brashy, A; Talaat, W, )	0.4
" It Given every 6 hr intramuscularly in patients for acute pain, to avoid frequent dosing and patient inconvenience Ketorolac from ethamine was found suitable for parenteral depot system by biodegradable microspheres for the present study."	( Development, characterization, and evaluation of ketorolac tromethamine-loaded biodegradable microspheres as a depot system for parenteral delivery. Sinha, VR; Trehan, A, 2008)	0.6
"This was a randomized-sequence, open-label, single-dose, 2-period crossover (2 dosing periods x 2 treatments) study comparing the bioavailability of two 30-mg sublingual tablet formulations of ketorolac."	( Bioavailability of two sublingual formulations of ketorolac tromethamine 30 mg: a randomized, open-label, single-dose, two-period crossover comparison in healthy Mexican adult volunteers. Burke-Fraga, V; de Lago, A; Galán-Herrera, JF; González-de la Parra, M; Jiménez, P; López-Bojórquez, E; Maya-Barrios, JA; Namur, S; Oliva, I; Poo, JL, 2008)	0.6
" The formulation was optimized for skin permeation enhancers, pH of the system, and dosage strength using in vitro and in vivo techniques."	( Ketorolac tromethamine transdermal gel: development, in vitro and in vivo evaluation. Bommagani, M; Dubey, R; Karnati, HR; Menon, VC; Mullangi, R; Thammera, RK; Venkateswarlu, V, 2009)	1.8
") dosing regimen."	( Aqueous prostaglandin E(2) of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing. Bucci, FA; Waterbury, LD, 2009)	0.35
" The article gives an overview of the main concepts used thus far to design various pharmaceutical dosage forms for the therapeutically effective delivery of the drug candidate through various routes."	( Ketorolac tromethamine formulations: an overview. Kumar, RV; Singh, G; Sinha, VR, 2009)	1.8
" In protocol 1 (n = 18), a dose-response curve to intrabrachial infusion of ATP was performed before and after both single and combined inhibition of NO synthase [N(G)-monomethyl-L-arginine (L-NMMA)] and cyclooxygenase (ketorolac)."	( Mechanisms of ATP-mediated vasodilation in humans: modest role for nitric oxide and vasodilating prostaglandins. Crecelius, AR; Dinenno, FA; Garcia, LJ; Kirby, BS; Larson, DG; Luckasen, GJ; Richards, JC; Voyles, WF, 2011)	0.37
"Although dose-response curves are commonly used to describe in vivo cutaneous α-adrenergic responses, modeling parameters and analyses methods are not consistent across studies."	( Pharmacological curve fitting to analyze cutaneous adrenergic responses. Davis, SL; Stachenfeld, NS; Wenner, MM; Wilson, TE, 2011)	0.37
"The intranasal dosing in adolescents was well tolerated with minimal adverse effects."	( The pharmacokinetics of ketorolac after single postoperative intranasal administration in adolescent patients. Anderson, BJ; Drover, DR; Hammer, GB, 2012)	0.38
"75 mg (one spray to one nostril) in this patient population is recommended based on similar dosing adjustments made for intramuscular ketorolac tromethamine."	( Comparison of intranasal ketorolac tromethamine pharmacokinetics in younger and older adults. Bullingham, R; Juan, A, 2012)	0.89
" DuraSite formulations may lessen the side effects associated with topical nonsteroidal anti-inflammatory drug use by maintaining efficacy with a reduced dosing regimen and reduced active ingredient."	( Aqueous humor penetration of ketorolac formulated in DuraSite or DuraSite 2 delivery systems compared to Acular LS in rabbits. Bowman, LM; Hosseini, K; Hou, E; Shafiee, A, 2013)	0.39
"A validated and highly selective high-performance thin-layer chromatography (HPTLC) method was developed for the determination of ketorolac tromethamine (KTC) with phenylephrine hydrochloride (PHE) (Mixture 1) and with febuxostat (FBX) (Mixture 2) in bulk drug and in combined dosage forms."	( Development and Validation of a High-Performance Thin-Layer Chromatographic Method for the Simultaneous Determination of Two Binary Mixtures Containing Ketorolac Tromethamine with Phenylephrine Hydrochloride and with Febuxostat. El Yazbi, FA; Hamdy, MM; Hassan, EM; Khamis, EF; Ragab, MA, )	0.53
"The present investigation explores the development and characterization of moxifloxacin hydrochloride and ketorolac tromethamine combination loaded Eudragit RL 100 nanosuspension for ocular drug delivery in order to overcome the problems associated with conventional dosage forms."	( Eudragit RL100 Based Moxifloxacin Hydrochloride and Ketorolac Tromethamine Combination Nanoparticulate System for Ocular Drug Delivery. Pawar, P; Salvi, V, 2020)	1.02
" There was no significant difference in the dosage of sufentanil, propofol, remifentanil and vecuronium, the incidence of nausea and vomiting, the delay of recovery, dizziness, drowsiness or respiratory depression between the two groups (P > 0."	( Ketorolac tromethamine pretreatment suppresses sufentanil-induced cough during general anesthesia induction: a prospective randomized controlled trial. Chen, B; Hu, B; Miao, M; Tian, Z; Wang, L; Zhang, L, 2020)	2
" The second phase was similar to the first, except each treatment was administered at a dosage of 1 drop/eye, twice daily for 5 days and CS was measured before treatment initiation and at 15 minutes and 24 and 48 hours after the last dose."	( Effects of topical instillation of 0.1% diclofenac sodium, 0.5% ketorolac tromethamine, and 0.03% flurbiprofen sodium on corneal sensitivity in ophthalmologically normal cats. Meekins, JM; Rankin, AJ; Roberts, JK; Roush, JK, 2021)	0.86
" Operation time, awakening time (time from drug withdrawal to consciousness recovery), the dosage of propofol, sufentanil, remifentanil, and intraoperative vasoactive drug dosage were recorded to compare."	( Effect of ketorolac tromethamine combined with dezocine prior administration on hemodynamics and postoperative analgesia in patients undergoing laparoscopic hernia repair. Cai, Z; Fu, B; Kang, Y; Li, Y; Wang, J; Wu, Y, 2022)	1.12
" At the same time, the application of ketorolac tromethamine can reduce the dosage of remifentanil and inhibit the occurrence of adverse reactions when used alone."	( Effect of Ketorolac Tromethamine Combined With Remifentanil on Reducing Complications During the General Anesthesia Emergence. Cao, H; Chang, J; Ran, R; Wang, Y; Xiao, Y; Zhang, X, 2023)	1.58
" Multiple standard addition method was applied to enable the determination of OLO which is considered as the weakly absorbing species as well as the minor component in a challenging dosage form ratio (4:1)."	( UV spectrophotometric methods for simultaneous determination of ketorolac tromethamine and olopatadine hydrochloride: Application of multiple standard addition for assay of ophthalmic solution. El-Malla, SF; Hammad, SF; Rady, MM, 2023)	1.15

Role	Description
analgesic	An agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms.
cyclooxygenase 2 inhibitor	A cyclooxygenase inhibitor that interferes with the action of cyclooxygenase 2.
cyclooxygenase 1 inhibitor	A cyclooxygenase inhibitor that interferes with the action of cyclooxygenase 1.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
organoammonium salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Luciferase	Photinus pyralis (common eastern firefly)	Potency	12.3018	0.0072	15.7588	89.3584	AID1224835
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	22.0846	0.0060	38.0041	19,952.5996	AID1159521; AID1159523
SMAD family member 2	Homo sapiens (human)	Potency	21.3138	0.1737	34.3047	61.8120	AID1346859
SMAD family member 3	Homo sapiens (human)	Potency	21.3138	0.1737	34.3047	61.8120	AID1346859
GLI family zinc finger 3	Homo sapiens (human)	Potency	5.3080	0.0007	14.5928	83.7951	AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	20.1005	0.0002	21.2231	8,912.5098	AID1259247; AID743036; AID743053; AID743054
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	17.4596	0.0010	22.6508	76.6163	AID1224838; AID1224839; AID1224893
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	12.8499	0.0030	41.6115	22,387.1992	AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	22.4209	0.0015	30.6073	15,848.9004	AID1224820; AID1224821
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	12.6151	0.0002	29.3054	16,493.5996	AID1259244; AID743069; AID743075
cytochrome P450 2D6	Homo sapiens (human)	Potency	13.8029	0.0010	8.3798	61.1304	AID1645840
Parkin	Homo sapiens (human)	Potency	9.2000	0.8199	14.8306	44.6684	AID720573
aryl hydrocarbon receptor	Homo sapiens (human)	Potency	11.8832	0.0007	23.0674	1,258.9301	AID743085
Bloom syndrome protein isoform 1	Homo sapiens (human)	Potency	0.0010	0.5406	17.6392	96.1227	AID2364; AID2528
histone deacetylase 9 isoform 3	Homo sapiens (human)	Potency	6.3030	0.0376	17.0823	61.1927	AID1259364; AID1259388
huntingtin isoform 2	Homo sapiens (human)	Potency	3.9811	0.0006	18.4198	1,122.0200	AID2669
geminin	Homo sapiens (human)	Potency	1.2589	0.0046	11.3741	33.4983	AID624297
Voltage-dependent calcium channel gamma-2 subunit	Mus musculus (house mouse)	Potency	29.8493	0.0015	57.7890	15,848.9004	AID1259244
Cellular tumor antigen p53	Homo sapiens (human)	Potency	33.4915	0.0023	19.5956	74.0614	AID651631
Glutamate receptor 2	Rattus norvegicus (Norway rat)	Potency	29.8493	0.0015	51.7393	15,848.9004	AID1259244
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	39.8107	0.0096	10.5250	35.4813	AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	2.7000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	133.0000	0.1100	7.1903	10.0000	AID1473738
Prostaglandin G/H synthase 2	Homo sapiens (human)	IC50 (µMol)	30.3100	0.0001	0.9950	10.0000	AID664058; AID664059
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
prostaglandin biosynthetic process	Prostaglandin G/H synthase 2	Homo sapiens (human)
angiogenesis	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to oxidative stress	Prostaglandin G/H synthase 2	Homo sapiens (human)
embryo implantation	Prostaglandin G/H synthase 2	Homo sapiens (human)
learning	Prostaglandin G/H synthase 2	Homo sapiens (human)
memory	Prostaglandin G/H synthase 2	Homo sapiens (human)
regulation of blood pressure	Prostaglandin G/H synthase 2	Homo sapiens (human)
negative regulation of cell population proliferation	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to xenobiotic stimulus	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to nematode	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to fructose	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to manganese ion	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of vascular endothelial growth factor production	Prostaglandin G/H synthase 2	Homo sapiens (human)
cyclooxygenase pathway	Prostaglandin G/H synthase 2	Homo sapiens (human)
bone mineralization	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of prostaglandin biosynthetic process	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of fever generation	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of synaptic plasticity	Prostaglandin G/H synthase 2	Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergic	Prostaglandin G/H synthase 2	Homo sapiens (human)
prostaglandin secretion	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to estradiol	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to lipopolysaccharide	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to vitamin D	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to heat	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to tumor necrosis factor	Prostaglandin G/H synthase 2	Homo sapiens (human)
maintenance of blood-brain barrier	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of protein import into nucleus	Prostaglandin G/H synthase 2	Homo sapiens (human)
hair cycle	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of apoptotic process	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of nitric oxide biosynthetic process	Prostaglandin G/H synthase 2	Homo sapiens (human)
negative regulation of cell cycle	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of vasoconstriction	Prostaglandin G/H synthase 2	Homo sapiens (human)
negative regulation of smooth muscle contraction	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of smooth muscle contraction	Prostaglandin G/H synthase 2	Homo sapiens (human)
decidualization	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Prostaglandin G/H synthase 2	Homo sapiens (human)
regulation of inflammatory response	Prostaglandin G/H synthase 2	Homo sapiens (human)
brown fat cell differentiation	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to glucocorticoid	Prostaglandin G/H synthase 2	Homo sapiens (human)
negative regulation of calcium ion transport	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to fatty acid	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to mechanical stimulus	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to lead ion	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to ATP	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to hypoxia	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to non-ionic osmotic stress	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to fluid shear stress	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of transforming growth factor beta production	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesis	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of fibroblast growth factor production	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of brown fat cell differentiation	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of platelet-derived growth factor production	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular oxidant detoxification	Prostaglandin G/H synthase 2	Homo sapiens (human)
regulation of neuroinflammatory response	Prostaglandin G/H synthase 2	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to homocysteine	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to angiotensin	Prostaglandin G/H synthase 2	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
peroxidase activity	Prostaglandin G/H synthase 2	Homo sapiens (human)
prostaglandin-endoperoxide synthase activity	Prostaglandin G/H synthase 2	Homo sapiens (human)
protein binding	Prostaglandin G/H synthase 2	Homo sapiens (human)
enzyme binding	Prostaglandin G/H synthase 2	Homo sapiens (human)
heme binding	Prostaglandin G/H synthase 2	Homo sapiens (human)
protein homodimerization activity	Prostaglandin G/H synthase 2	Homo sapiens (human)
metal ion binding	Prostaglandin G/H synthase 2	Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen	Prostaglandin G/H synthase 2	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
plasma membrane	Glutamate receptor 2	Rattus norvegicus (Norway rat)
nuclear inner membrane	Prostaglandin G/H synthase 2	Homo sapiens (human)
nuclear outer membrane	Prostaglandin G/H synthase 2	Homo sapiens (human)
cytoplasm	Prostaglandin G/H synthase 2	Homo sapiens (human)
endoplasmic reticulum	Prostaglandin G/H synthase 2	Homo sapiens (human)
endoplasmic reticulum lumen	Prostaglandin G/H synthase 2	Homo sapiens (human)
endoplasmic reticulum membrane	Prostaglandin G/H synthase 2	Homo sapiens (human)
caveola	Prostaglandin G/H synthase 2	Homo sapiens (human)
neuron projection	Prostaglandin G/H synthase 2	Homo sapiens (human)
protein-containing complex	Prostaglandin G/H synthase 2	Homo sapiens (human)
neuron projection	Prostaglandin G/H synthase 2	Homo sapiens (human)
cytoplasm	Prostaglandin G/H synthase 2	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID588209	Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset	2010	Chemical research in toxicology, Jul-19, Volume: 23, Issue:7	Developing structure-activity relationships for the prediction of hepatotoxicity.
AID664061	Inhibition of ibuprofen binding to sheep placenta COX2 at compound/protein ratio of 100:1 where in compound added previously followed by addition of ibuprofen by saturation transfer difference 1[H]NMR spectroscopy	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Binding of ibuprofen, ketorolac, and diclofenac to COX-1 and COX-2 studied by saturation transfer difference NMR.
AID664055	Reversible binding to ram seminal vesicle COX1 at 300 uM at 600 MHz and 37 degC by saturation transfer difference 1[H]NMR spectroscopy	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Binding of ibuprofen, ketorolac, and diclofenac to COX-1 and COX-2 studied by saturation transfer difference NMR.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID664060	Inhibition of ibuprofen binding to sheep placenta COX2 at compound/protein ratio of 100:1 where in ibuprofen added previously followed by addition of compound by saturation transfer difference 1[H]NMR spectroscopy	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Binding of ibuprofen, ketorolac, and diclofenac to COX-1 and COX-2 studied by saturation transfer difference NMR.
AID664054	Reversible binding to sheep placenta COX2 at 300 uM at 600 MHz and 37 degC by saturation transfer difference 1[H]NMR spectroscopy	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Binding of ibuprofen, ketorolac, and diclofenac to COX-1 and COX-2 studied by saturation transfer difference NMR.
AID1175391	Inhibition of human TRPV1 overexpressed in BEAS-2B cells assessed as residual activity at 250 uM after 30 mins by Fluo-4 AM fluorescence assay	2014	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 24, Issue:24	Inhibition of FAAH, TRPV1, and COX2 by NSAID-serotonin conjugates.
AID588210	Human drug-induced liver injury (DILI) modelling dataset from Ekins et al	2010	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12	A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID664058	Inhibition of human COX2 measured after pre-incubation of enzyme with compound	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Binding of ibuprofen, ketorolac, and diclofenac to COX-1 and COX-2 studied by saturation transfer difference NMR.
AID1175392	Inhibition of human TRPV1 overexpressed in BEAS-2B cells assessed as residual activity at 50 uM after 30 mins by Fluo-4 AM fluorescence assay	2014	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 24, Issue:24	Inhibition of FAAH, TRPV1, and COX2 by NSAID-serotonin conjugates.
AID521220	Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay	2007	Nature chemical biology, May, Volume: 3, Issue:5	Chemical genetics reveals a complex functional ground state of neural stem cells.
AID664059	Instantaneous inhibition of human COX2 measured immediately after incubation of enzyme with compound	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Binding of ibuprofen, ketorolac, and diclofenac to COX-1 and COX-2 studied by saturation transfer difference NMR.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	21 (3.68)	18.7374
1990's	233 (40.88)	18.2507
2000's	147 (25.79)	29.6817
2010's	130 (22.81)	24.3611
2020's	39 (6.84)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	249 (38.31%)	5.53%
Reviews	27 (4.15%)	6.00%
Case Studies	62 (9.54%)	4.05%
Observational	1 (0.15%)	0.25%
Other	311 (47.85%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (133)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Disposition of Intravenous Ketorolac After Cesarean Section [NCT01291472]	Phase 4	42 participants (Actual)	Interventional	2011-06-30	Completed
[NCT01339624]		65 participants (Actual)	Interventional	2009-01-31	Completed
Single Site Pharmacokinetic Non-interaction Study With Open-label, Randomized, Single-dose, Three-period, Six-sequence, Crossover Design to Compare Tramadol Hydrochloride 25 mg Capsules (Tradol [Trade Mark], Product of Grünenthal Mexico S.A. de C.V.) and [NCT03767036]	Phase 1	30 participants (Actual)	Interventional	2017-06-05	Completed
Opioid-Free Shoulder Arthroplasty [NCT03540030]	Phase 4	86 participants (Actual)	Interventional	2016-09-30	Completed
Randomized, Prospective Study of the Assessment, Prevention and Management of Acute Post-herniotomy Pain [NCT01345162]	Phase 4	200 participants (Actual)	Interventional	2010-03-31	Completed
National, Multicenter, Randomized, Double-blind, Triple-dummy, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Escócia Association in the Treatment of Acute Pain [NCT04666701]	Phase 2	0 participants (Actual)	Interventional	2023-02-28	Withdrawn(stopped due to Strategy review)
Comparison Between the Effects of Intravenous Morphine, Tramadol and Ketorolac on Stress and Immune Responses in Patients Undergoing Modified Radical Mastectomy [NCT02449954]	Phase 2/Phase 3	60 participants (Actual)	Interventional	2014-06-30	Active, not recruiting
Prospective Randomized Double-blind Study of Incisional Local Anesthesia in Laparoscopic Surgery (Ketorolac Versus Normal Saline) [NCT01374828]	Phase 4	0 participants (Actual)	Interventional	2012-01-31	Withdrawn(stopped due to lack of funding)
A Randomized, Double-blind, Placebo-controlled, Parallel, Single-dose Study of Intranasal Ketorolac in the Treatment of Pain Secondary to Dental Impaction Surgery [NCT01356225]	Phase 2	80 participants (Actual)	Interventional	2004-02-29	Completed
Open Label, 2-Way Crossover Study to Assess the PK of Intranasal Ketorolac Tromethamine and to Assess the Effects of a Single Dose of Oxymetazoline Hydrochloride on the PK of Intranasal Ketorolac Tromethamine in Healthy Male Subjects [NCT01363089]	Phase 1	21 participants (Actual)	Interventional	2007-01-31	Completed
Intranasal Ketorolac Versus Intravenous Ketorolac for Treatment of Migraine Headaches in Children: A Randomized Non-inferiority Clinical Trial [NCT02358681]	Phase 3	59 participants (Actual)	Interventional	2015-06-16	Completed
Analgesic Efficacy of Intra-muscular Ketamine-ketorolac Versus Fentanyl- Ketorolac for Children Undergoing Bone Marrow Biopsy and Aspiration [NCT03649334]	Phase 4	80 participants (Actual)	Interventional	2018-08-26	Completed
Efficacy and Cost-effectiveness of Intra-Articular Ketorolac Injection for Knee Osteoarthritis: A Randomized, Controlled, Double-Blinded Study [NCT03694821]	Phase 4	18 participants (Actual)	Interventional	2018-07-05	Terminated(stopped due to Low enrollment)
A Phase 3, Double-blind, Randomized Study of the Safety, Tolerability, and Analgesic Efficacy of Multiple Doses of Ketorolac Tromethamine Administered Intranasally for Postoperative Pain [NCT01347853]	Phase 3	300 participants (Actual)	Interventional	2003-06-30	Completed
Local Infiltration Analgesia in Total Hip Arthroplasty - Efficacy of Multiple Bolus Injections With Ropivacaine and Ketorolac [NCT01344395]	Phase 4	80 participants (Actual)	Interventional	2010-03-31	Completed
A Phase 1, Double-Blind, Study of the Tolerability of Formulations of Ketorolac Tromethamine Following Intranasal Administration in Healthy Volunteers [NCT01363063]	Phase 1	40 participants (Actual)	Interventional	2006-12-31	Completed
A Single Arm, Open Label Study of the Safety, Efficacy, and Pharmacokinetics of SPRIX (Intranasal Ketorolac Tromethamine) in 0 to 11 Year-Old Patients Undergoing Open Surgical Procedures [NCT02102516]	Phase 3	45 participants (Actual)	Interventional	2014-03-31	Completed
Comparison of the Analgesic Effect of Femoral Nerve Block, Intraarticular Infiltration or a Combination of Both in the Control of Pain in Total Knee Arthroplasty [NCT01304212]	Phase 4	137 participants (Actual)	Interventional	2011-04-30	Completed
Effect of Toradol on Post-operative Foot and Ankle Healing [NCT03727048]	Phase 4	128 participants (Actual)	Interventional	2016-08-31	Completed
Ketorolac Versus Triamcinolone Intra-articular Knee Injections for the Treatment of Osteoarthritis. A Prospective, Double-Blinded Randomized Trial [NCT02295189]		36 participants (Actual)	Interventional	2013-01-31	Completed
The Effect of Protracted Saphenous Nerve and Obturator Nerve Block Versus Saphenous Nerve Block Versus Local Infiltration Analgesia on Opioid Consumption, Pain, Block Duration of Action and Mobilization After Total Knee Arthroplasty. [NCT02067078]	Phase 4	75 participants (Actual)	Interventional	2014-02-28	Completed
Atomized Intranasal Vs Intravenous Ketorolac in Acute Renal Colic Pain Management: A Randomized Controlled Double-blinded Clinical Trial. [NCT04441762]	Phase 2/Phase 3	171 participants (Actual)	Interventional	2020-12-30	Completed
Prophylactic Effect of Ketorolac Tromethamine on the Cystoid Macular Edema After Phacoemulsification in Diabetic Patients [NCT03551808]	Phase 2	102 participants (Anticipated)	Interventional	2017-01-01	Recruiting
Intravenous Ketorolac Vs. Morphine In Children Presenting With Acute Abdominal Pain And/or Suspected Appendicitis: A Multi-centre Non-Inferiority Randomized Controlled Trial [NCT06160778]	Phase 3	495 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Analgesic Efficacy, Safety and Tolerability of Intravenous N1539 in Subjects After Abdominal Laparoscopic Surgery [NCT01436032]	Phase 3	50 participants (Actual)	Interventional	2011-10-31	Terminated
Ketorolac Plus Tobramycin/Dexamethasone vs. Tobramycin/Dexamethasone After Uneventful Phacoemulsification Surgery [NCT01103401]		145 participants (Actual)	Interventional	2009-10-31	Completed
Scintigraphic Assessment of Nasal Deposition and Clearance of 99mTc DTPA Ketorolac Solution Administered Using the Valois Nasal Spray Device [NCT01356212]	Phase 1	13 participants (Actual)	Interventional	2002-09-30	Completed
Intraoperative Ketorolac Dose of 15 mg Versus the Standard 30 mg on Early Postoperative Pain After Spine Surgery: A Randomised, Blinded, Non-Inferiority Trial [NCT01230463]		50 participants (Anticipated)	Interventional	2010-09-30	Recruiting
[NCT01258309]	Phase 3	129 participants (Actual)	Interventional	2010-12-31	Completed
Efficacy of Ketorolac and Lidocaine Inferior Alveolar Nerve Blocks in Patients With With Symptomatic Irreversible Pulpitis: a Prospective Double Blind, Randomized Clinical Trial [NCT03410212]	Phase 2	60 participants (Actual)	Interventional	2018-02-15	Completed
A Prospective Randomized Trial Comparing Femoral Nerve Black to Intraoperative Local Anesthetic Injection of Liposomal Bupivacaine (Exparel) in Total Knee Replacement [NCT02473198]	Phase 3	312 participants (Anticipated)	Interventional	2014-01-31	Active, not recruiting
Subacromial Injection of Methylprednisolone Versus Ketorolac to Treat Shoulder Impingement: a Double-blind Randomized Controlled Trial [NCT03913702]	Phase 2	1 participants (Actual)	Interventional	2019-09-09	Terminated(stopped due to Inadequate patient enrollment)
Short-term Additive Effect of Topical Ketorolac on the Management of Diabetic Macular Edema With Intravitreal Bevacizumab [NCT04119921]	Phase 2/Phase 3	26 participants (Actual)	Interventional	2018-01-01	Completed
Early Versus Late Deflation of Distal Tourniquet in Intravenous Regional Anesthesia With and Without Ketorolac in Hand & Forearm Surgery [NCT05234619]		80 participants (Anticipated)	Interventional	2022-01-01	Active, not recruiting
Fluoroscopic Guided Radiofrequency of Genicular Nerves for Pain Alleviation in Chronic Knee Osteoarthritis : A Single-blind Randomized Controlled Trial. [NCT03224637]		60 participants (Actual)	Interventional	2014-07-31	Completed
PROUD Study - Preventing Opioid Use Disorders [NCT04766996]	Phase 4	57 participants (Actual)	Interventional	2021-05-17	Terminated(stopped due to Loss of surgery team member deemed the study procedures impossible to achieve, and no replacement could be found in a timely manner to complete trial as initially planned.)
A Randomized Blinded Placebo Controlled Trial Assessing Ketorolac (Toradol) at Oocyte Retrieval [NCT06026553]	Phase 1	400 participants (Anticipated)	Interventional	2022-08-10	Recruiting
A Phase 2, Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability, and Analgesic Efficacy of Ketorolac Tromethamine Administered Intranasally for the Acute Treatment of Migraine [NCT00483717]	Phase 2	173 participants (Actual)	Interventional	2007-07-31	Completed
Prospective Evaluation of the Effects of IV Ketorolac on Platelet Function Post-Cesarean Delivery [NCT03805607]	Phase 4	40 participants (Actual)	Interventional	2021-01-18	Active, not recruiting
The Effect of Preoperative Topical Ketorolac 0.45% on Aqueous Cytokine Levels and Macular Thickness in Diabetic and Non Diabetic Patients Undergoing Cataract Surgery [NCT02646072]	Phase 4	80 participants (Actual)	Interventional	2014-08-31	Completed
Pre-operative Ketorolac Administration Has no Pre-emptive Analgesic Effect Following Total Abdominal Hysterectomy [NCT02642718]	Phase 4	48 participants (Actual)	Interventional	2001-04-30	Completed
Autonomic Control of the Circulation and the Venous Distension Reflex [NCT03513770]	Early Phase 1	18 participants (Anticipated)	Interventional	2019-08-14	Recruiting
Efficacy of Ketorolac Buccal Infiltration on Success Rate of Inferior Alveolar Nerve Block in Patients With Irreversible Pulpitis: A Prospective, Randomized, Double-blind Clinical Trial [NCT02536430]	Phase 2	40 participants (Actual)	Interventional	2015-03-31	Completed
A Placebo-controlled, Randomized, Clinical Trial of Prophylactic Ketorolac 0.5% in Patients Undergoing Pars Plana Vitrectomy and Phacovitrectomy Epiretinal Membrane Peel Surgery: Assessing Macular Volume With Spectral-domain OCT [NCT00974753]		18 participants (Actual)	Interventional	2010-03-31	Completed
Premedication Efficacy of Oral Ketorolac and Ketorolac/ Acetaminophen on Post Endodontic Treatment Pain [NCT02614118]	Phase 2	66 participants (Actual)	Interventional	2015-09-30	Completed
Comparison of Patient-controlled Analgesia With Background Opioid Versus Non-opioid Infusion for Postoperative Pain in Patients Undergoing Total Knee Arthroplasty: a Randomized, Non-inferiority Study [NCT05861791]		98 participants (Anticipated)	Interventional	2023-02-07	Recruiting
Comparison of Ketorolac and Ketorolac/Acetaminophen on Success of Inferior Alveolar Nerve Block Injection [NCT02601911]	Phase 2	60 participants (Actual)	Interventional	2015-09-30	Completed
Effect of Anti-inflammatory Topical Prednisolone Acetate 1%, Nepafenac of 0.1% and Ketorolac Tromethamine 0.4% in Intra-operative Mydriasis in Facetectomies [NCT00865540]	Phase 4	30 participants (Actual)	Interventional	2009-03-31	Active, not recruiting
Efficacy and Safety of Topic Ketorolac to Treat Center Point Thickness Secondary to Panphotocoagulation in Proliferative Diabetic Retinopathy [NCT00907114]	Phase 2	44 participants (Actual)	Interventional	2009-06-30	Completed
Esketamine vs. Ketorolac for Prevention of Postoperative Pain and Cognitive Dysfunction After Total Knee Arthroplasty in Patients: a Randomized Double-blind Controlled Trial [NCT05132595]		160 participants (Anticipated)	Interventional	2021-11-30	Recruiting
Periarticular Injection and Hamstring Block Versus Placebo for Pain Control in Anterior Cruciate Ligament Reconstruction: A Randomized Controlled Trial [NCT05248724]		44 participants (Actual)	Interventional	2017-08-01	Completed
Acute Pain and Role of Ketolorac in Inflammatory Mediators After Knee Arthroscopy Evaluated by Microdialysis [NCT00774540]	Phase 4	40 participants (Actual)	Interventional	2008-08-31	Completed
Evaluation of Post-operative Pain and Expression of IL-8 Using Ketolac or Cryo-irrigation as a Final Flush in Single Visit Endodontic Treatment in Teeth With Symptomatic Irreversible Pulpitis and Apical Periodontitis.Randomized Clinical Trial. [NCT04733326]	Phase 1	39 participants (Anticipated)	Interventional	2021-04-01	Not yet recruiting
Single Blind RCT to Evaluate the Effect of Ketorolac in Upper Extremity Tendinopathy and Arthropathy [NCT05292339]	Phase 4	160 participants (Anticipated)	Interventional	2023-01-31	Recruiting
A Double-Blind, Randomized, Placebo- and Active-Comparator-Controlled, Single-Dose Study to Assess the Efficacy of KAI-1678 Administered by Subcutaneous Infusion for the Treatment of Postoperative Pain [NCT01015235]	Phase 2	90 participants (Actual)	Interventional	2008-12-31	Completed
Efficiency of Multi-Modal Anesthesia (MMA) Protocol in Pain Control and Analgesia in Patients Undergoing Posterior Lumbar Spinal Fusion Surgery [NCT05413902]	Phase 4	100 participants (Actual)	Interventional	2021-04-05	Completed
Efficacy and Safety of Intranasal Ketorolac Tromethamine (SPRIX) as a Short Term Pain Management Tool for Adult Male Patients With Post-Vasectomy Pain [NCT02000388]	Phase 4	15 participants (Anticipated)	Interventional	2012-02-29	Enrolling by invitation
To Evaluate the Efficacy, Tolerability, and Safety of Intranasal Ketorolac Tromethamine (Sprix) as an Option for Acute (up to 5 Days) Pain Management Adult Interstitial Cystitis Patients Experiencing a Flare of Pain [NCT02000401]	Phase 4	15 participants (Actual)	Interventional	2012-05-31	Completed
Preoperative Ketorolac for Intraoperative and Postoperative Pain Management in Scleral Buckling Surgery Under Retrobulbar Block Anesthesia: A Prospective, Randomized, Controlled Study [NCT02729285]	Phase 4	73 participants (Actual)	Interventional	2014-07-31	Completed
Open Label Randomized Study for Evaluating Efficacy and Safety of Ketorolac Tromethamine and Ketoprofen in Gel in Patients With Gonarthrosis and Low Back Pain [NCT02638831]	Phase 4	240 participants (Actual)	Interventional	2013-03-31	Completed
Post Operative Pain and Expression of Substance P, IL8 After the Use of Ketorolac Irrigant Following Single Visit Root Canal Treatment [NCT04319549]		44 participants (Anticipated)	Interventional	2020-08-01	Not yet recruiting
Opiate Free Multimodal Pain Pathway in Elective Foot and Ankle Surgery: A Prospective Study [NCT04771741]		72 participants (Actual)	Observational	2020-12-01	Completed
A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Active and Placebo-Controlled Trial to Evaluate the Analgesic Efficacy and Safety of NTM-001 for the Treatment of Moderately Severe Postoperative Pain Following Bunionectomy [NCT05324358]	Phase 3	360 participants (Anticipated)	Interventional	2022-11-15	Recruiting
Trigger Point Injection for Myofascial Pain Syndrome in the Low Back (T-PIMPS): A Randomized Controlled Trial. [NCT04704297]	Phase 4	180 participants (Anticipated)	Interventional	2020-12-28	Recruiting
A 3-Month Clinical Safety Comparison of Nevanac 0.1% to Acular LS 0.4% and Vehicle Following Cataract Surgery [NCT00332774]	Phase 3	149 participants (Actual)	Interventional	2006-02-28	Completed
Perioperative Ketorolac in High Risk Breast Cancer Patients With and Without Inflammation. A Prospective Randomized Placebo-controlled Trial. [NCT01806259]	Phase 3	203 participants (Actual)	Interventional	2013-02-28	Completed
The Analgesic Efficacy of Adding Magnesium Sulfate Versus Ketorolac to Bupivacaine in Ultrasound-guided Supraclavicular Brachial Plexus Block (A Prospective- Double-blinded Randomized Controlled Trial) [NCT04554862]	Phase 4	80 participants (Actual)	Interventional	2019-10-01	Completed
Tobramycin 0.3% - Dexamethasone 0.1% Versus Tobramycin 0.3% - Dexamethasone 0.1% Plus Ketorolac Tromethamine 0.5% After Phacoemulsification Surgery. A Randomized Trial [NCT00992355]		97 participants (Actual)	Interventional	2009-01-31	Completed
A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail, Xibrom and Nevanac in Patients Undergoing Phacoemulsification [NCT01021761]	Phase 4	126 participants (Actual)	Interventional	2009-10-31	Completed
A Randomized Trial Comparing the Combination of Intravenous Lidocaine and Ketorolac to Either Analgesics Alone for ED Patients With Acute Renal Colic [NCT02902770]	Phase 4	150 participants (Actual)	Interventional	2016-10-31	Completed
Effect of Ketorolac Premedication on Anesthetic Efficiency of Inferior Alveolar Nerve Block, Pre-Treatment and Post-Endodontic Pain in Teeth With Irreversible Pulpitis: A Randomized Controlled Double Blinded Trial [NCT02940405]		38 participants (Anticipated)	Interventional	2017-01-31	Not yet recruiting
Comparison of Ketorolac at Three Doses in Children With Acute Pain: A Randomized Controlled Trial [NCT05641363]	Phase 3	171 participants (Anticipated)	Interventional	2023-06-01	Recruiting
A Prospective, Randomized, Pilot Study of Preoperative Anti-Inflammatory Therapy for Ureteral Stent Symptoms [NCT03638999]	Early Phase 1	36 participants (Anticipated)	Interventional	2018-07-31	Recruiting
Randomized, Double Blind, Double Dummy To Non-Inferiority Comparison Of Ketorolac Tromethamine Versus Naproxen For Moderate to Severe Back Pain Treatment [NCT01471886]	Phase 3	83 participants (Actual)	Interventional	2013-03-31	Completed
Randomized, Double Blind, Double Dummy To Non-Inferiority Comparison Of Ketorolac Tromethamine Oral Drops Versus Naproxen For Moderate to Severe Back Pain Treatment [NCT01471899]	Phase 3	78 participants (Actual)	Interventional	2013-03-31	Completed
A Randomized Controlled Trial to Assess the Pain-control Efficacy of Intra-articular Toradol Compared to Oral NSAIDs: A Pilot Study [NCT02966288]	Phase 4	0 participants (Actual)	Interventional	2017-01-31	Withdrawn(stopped due to poor enrollment)
Multimodal Management for Perioperative Analgesia in Otolaryngology - Head and Neck Free Flap Reconstructive Surgery: A Prospective Study [NCT04246697]	Phase 4	30 participants (Actual)	Interventional	2019-11-01	Completed
An Analgesia Protocol for Acute Renal Colic in the DHMC Emergency Department [NCT00504283]		45 participants (Anticipated)	Interventional	2007-02-28	Completed
Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects [NCT00469690]	Phase 4	58 participants (Actual)	Interventional	2007-05-31	Completed
A Phase 1, Open Label, Multiple Dose Study to Determine the Tolerability, Safety and Pharmacokinetics of Ketorolac Tromethamine by Intranasal Administration in Healthy Volunteers [NCT01363050]	Phase 1	15 participants (Actual)	Interventional	2006-01-31	Completed
A Phase 1 Safety and Pharmacokinetics Study of Intranasal Ketorolac in Elderly and Nonelderly Adult Healthy Subjects [NCT01365624]	Phase 1	30 participants (Actual)	Interventional	2008-02-29	Completed
Premedication Efficacy of Ketorolac Infiltration on Post Endodontic Pain [NCT02923687]	Phase 2	60 participants (Actual)	Interventional	2016-09-30	Completed
A Randomized, Masked Comparison of Topical Ketorolac 0,4% Versus Placebo in Cataract Surgery. [NCT01542190]	Phase 4	80 participants (Anticipated)	Interventional	2011-02-28	Completed
A Single Center, Prospective Randomized Double-blind Trial: Efficacy of Nefopam and Morphine in Balanced Analgesia for Acute Ureteric Colic [NCT01543165]	Phase 4	111 participants (Anticipated)	Interventional	2012-12-31	Recruiting
The Effectiveness of Bupivicaine Infusion Versus Intravenous Ketorolac for Postoperative Analgesia After Iliac Crest Bone Harvesting for Lefort I Osteotomy or Alveolar Cleft Repair. [NCT00405262]	Phase 3	54 participants (Actual)	Interventional	2006-05-31	Completed
Nepafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo (Nepafenac Vehicle) for the Prevention and Treatment of Ocular Inflammation and Ocular Pain Associated With Cataract Surgery: European Study [NCT00405730]	Phase 3	227 participants (Actual)	Interventional	2005-11-30	Completed
"A Prospective Randomized Double-Blind Trial Comparing 3 Doses of Intravenous Ketorolac for Pain Management in the Emergency Department" [NCT02078492]	Phase 4	240 participants (Actual)	Interventional	2014-03-31	Completed
Intravenous Ketorolac Vs. Morphine In Children Presenting With Suspected Appendicitis: A Pilot Single Center Non Inferiority Randomised Controlled Trial [NCT04528563]	Phase 3	105 participants (Actual)	Interventional	2021-05-05	Completed
Comparison of Intramuscular Ketorolac at Two Single-Dose Regimens for Treatment of Acute Musculoskeletal Pain in a Military Emergency Department: A Randomized Controlled Non-Inferiority Trial [NCT04763876]	Phase 4	110 participants (Actual)	Interventional	2020-06-27	Completed
Nitrous Oxide for Pain Management During In-office Transcervical Sterilization [NCT02312739]		72 participants (Actual)	Interventional	2014-02-28	Completed
Comparing Pain Outcomes of Intra-operative IV Tylenol and/or IV Toradol Administration for Carpal Tunnel Release and Distal Radius Fracture Surgeries [NCT02313675]	Phase 4	44 participants (Actual)	Interventional	2015-05-31	Completed
Efficacy of Multimodal Perioperative Analgesia Protocol With Periarticular Drug Injection in Total Knee Arthroplasty: A Randomized, Double Blind Study [NCT01042093]		160 participants (Actual)	Interventional	2010-01-31	Completed
A Phase 3, Double-Blind, Randomized Study of the Safety, Tolerability, and Analgesic Efficacy of Multiple Doses of Ketorolac Tromethamine Administered Intranasally for Postoperative Pain Following Major Abdominal Surgery [NCT00266786]	Phase 3	321 participants (Actual)	Interventional	2005-12-31	Completed
Effect of Prophylactic NSAID Drops on Cystoid Macular Edema After Cataract Surgery Using Optical Coherence Tomography [NCT00335439]		98 participants (Actual)	Interventional	2006-06-30	Completed
Open Label Study to Assess the Pharmacokinetics of Intranasal Ketorolac Tromethamine Following Multiple Doses of Fluticasone Propionate in Healthy Subjects [NCT01365611]	Phase 1	36 participants (Actual)	Interventional	2007-02-28	Completed
A Study of the Pharmacokinetics of Ketorolac Tromethamine Administered Intranasally (IN) for Postoperative Pain in Children Aged 12 Through 17 Years [NCT01363076]	Phase 1	20 participants (Actual)	Interventional	2007-06-30	Completed
Artificial Tears Versus Preservative Free Ketorolac Trometamol 0.45% for Treatment of Acute Viral Conjunctivitis [NCT01799863]	Phase 2/Phase 3	50 participants (Actual)	Interventional	2012-06-30	Completed
Comparison of a Pain Pump Versus Injectable Medication for Analgesia in Knee Arthroscopy [NCT01242644]	Phase 2	48 participants (Actual)	Interventional	2006-10-31	Completed
A Phase 1, Double-blind, 4-way Crossover Study of the Tolerability, Safety and Pharmacokinetics of 4 Formulations of Ketorolac Tromethamine by Intranasal Administration in Healthy Volunteers [NCT01355588]	Phase 1	16 participants (Actual)	Interventional	2005-08-31	Completed
Open Label, Three-Way Study to Assess the Absorption and Tolerability of Intranasal Ketorolac Tromethamine and to Assess the Effects of a Single Dose of Oxymetazoline Hydrochloride and Multiple Doses of Fluticasone Propionate on the Absorption and Tolerab [NCT01365650]	Phase 1	24 participants (Actual)	Interventional	2007-12-31	Completed
Toradol to Reduce Ureteroscopic Symptoms Trial [NCT03111381]	Phase 2	94 participants (Actual)	Interventional	2017-08-01	Completed
Pain Outcomes of Non-opioid Analgesia After Ureteroscopy or Percutaneous Nephrolithotomy for Nephrolithiasis: a Prospective Randomized Controlled Trial. [NCT03584373]	Phase 3	119 participants (Actual)	Interventional	2018-07-27	Completed
Postoperative Analgesia After Total Knee Arthroplasty. A Comparison of Continuous Epidural Infusion and Wound Infiltration With Continuous Intraarticular Infusion [NCT00421967]	Phase 4	80 participants (Actual)	Interventional	2007-01-31	Terminated(stopped due to Interim analysis)
Topical Application of ACULAR a Randomized, Vehicle Controlled Clinical Trial: Efficiency in Inhibiting Proliferative Retinopathy of Prematurity [NCT00634972]	Phase 4	83 participants (Actual)	Interventional	2005-11-30	Terminated(stopped due to The study could not be completed as the company producing this product interrupted their supply of this medication)
Ketorolac in Postoperative Infants: Pharmacokinetics and Safety [NCT01260883]	Phase 3	77 participants (Actual)	Interventional	2000-05-31	Completed
A Multicenter, Randomized, Open-Label, Phase II/III Clinical Trial Evaluating the Efficacy and Safety of a Fixed Combination of Ketorolac / Pitofenone / Fenpiverinium Compared to Active Control in Patients With Pain After Surgical Abdominal and Pelvic Ope [NCT05607641]	Phase 2/Phase 3	424 participants (Actual)	Interventional	2021-07-07	Completed
A Phase 1, Open-label Pharmacokinetic Study of Intravenous NTM-001 (A Novel Formulation of Ketorolac Tromethamine Applied by Continuous Intravenous Infusion From A Pre-Mixed Bag) in Healthy Chinese Subjects [NCT05382546]	Phase 1	16 participants (Actual)	Interventional	2022-05-23	Completed
A Double-Masked, Randomized, Single-Center Study Evaluating the Effect of 0.30% Ketorolac/0.80% HPMC, 0.80% HPMC and Vehicle on Symptoms of Dry Eye After Exposure to the Controlled Adverse Environment (CAE) [NCT03693183]	Phase 2	44 participants (Actual)	Interventional	2009-03-31	Terminated(stopped due to Study terminated by Sponsor)
Dosing of Ketorolac for Four Classes of Complaints in the Emergency Department [NCT03464461]	Phase 4	500 participants (Anticipated)	Interventional	2018-05-01	Active, not recruiting
Prospective Randomized Study Evaluating the Effect of Postoperative Ketorolac on Bone Healing and Opioid Consumption After First Metatarsophalangeal Joint Fusion [NCT04872283]	Phase 3	140 participants (Anticipated)	Interventional	2019-05-23	Enrolling by invitation
Efficacy of Combination Therapy With Intravenous Ketorolac and Metoclopramide for Pediatric Migraine Therapy in the Emergency Department [NCT01596166]	Phase 4	56 participants (Actual)	Interventional	2012-02-29	Completed
The Analgesic Efficacy of Continuous Infusion of Ketorolac and Ropivacaine at the Wound Site Using ON-Q Pump for Postoperative Pain Management [NCT00638508]	Phase 4	67 participants (Actual)	Interventional	2007-06-30	Completed
A Phase 2, Double-blind, Randomized Study of the Safety, Tolerability and Analgesic Efficacy of Multiple Doses of Ketorolac Tromethamine Administered Intranasally for Postoperative Pain [NCT01351090]	Phase 2	127 participants (Actual)	Interventional		Completed
Opioid-Free Pain Control Regiment Following Robotic Radical Prostatectomy: A Randomized Controlled Trial [NCT04939987]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2022-08-31	Withdrawn(stopped due to PI left institution and study was not transferred to new PI)
Human Cerebral Blood Flow Regulation: Sex, Mechanism, and Stress Differences [NCT04265053]	Early Phase 1	144 participants (Anticipated)	Interventional	2021-04-12	Recruiting
Low Dose Versus Normal Dose Ketorolac for Postoperative Pain After Prostatectomy and Hysterectomy: a Double-blind Randomized Controlled Non-inferiority Trial [NCT05206110]		100 participants (Anticipated)	Interventional	2022-04-21	Recruiting
Use of Perioperative Ketorolac in Breast Surgery to Reduce Post Operative Pain and Opioid Use [NCT04439396]	Phase 1	183 participants (Actual)	Interventional	2020-06-22	Completed
Continuous Infusion Versus Bolus Dosing for Pain Control After Pediatric Cardiothoracic Surgery [NCT02112448]		78 participants (Actual)	Interventional	2014-06-30	Completed
Psoas Compartment Block Versus Periarticular Local Anesthetic Infiltration for Pain Management for Total Hip Arthroplasty: A Prospective, Randomized Study [NCT02658149]	Phase 4	100 participants (Actual)	Interventional	2016-05-31	Completed
NSAID Use After Robotic Partial Nephrectomy (No-PAIN): a Randomized, Controlled Trial [NCT05842044]	Phase 2	110 participants (Anticipated)	Interventional	2023-09-15	Recruiting
IIT2021-16-Hendifar-KetoROCX: A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma [NCT05336266]	Early Phase 1	20 participants (Anticipated)	Interventional	2022-07-01	Recruiting
A Randomized Prospective Double Masked Controlled Trial Comparing Ketorolac Tromethamine 0.4% and Prednisolone Acetate 1% in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells. [NCT00478036]		31 participants (Actual)	Interventional	2007-05-31	Terminated(stopped due to insufficient enrollment)
A Multicenter, Prospective, Randomized, Double-blind Study to Determine the Efficacy of Intravenous Ibuprofen Compared to Intravenous Ketorolac for Pain Control Following Arthroscopic Knee Surgery [NCT01901393]	Phase 4	100 participants (Actual)	Interventional	2013-07-31	Completed
[NCT01836406]		16 participants (Actual)	Interventional	2012-12-31	Completed
A Pilot Trial to Study the Availability and Effect of Post-OP IV Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer, Cells Retrieved From the Peritoneal Cavity [NCT01670799]	Early Phase 1	29 participants (Actual)	Interventional	2012-03-31	Completed
A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% BID and Bromfenac 0.09% BID [NCT01023724]	Phase 4	50 participants (Actual)	Interventional	2009-12-31	Completed
A Comparison of Peak Aqueous Penetration of Acuvail, Xibrom, and Nevanac in Patients Undergoing Phacoemulsification [NCT01001806]	Phase 4	126 participants (Actual)	Interventional	2009-10-31	Completed
Ketorolac for Analgesia followiNG Autologous Breast RecOnstructiOn [NCT03007381]	Phase 4	0 participants (Actual)	Interventional	2017-11-30	Withdrawn(stopped due to No funding.)
Effect of Intrathecal Ketorolac on Mechanical Hypersensitivity After Total Hip Arthroplasty [NCT00621530]	Phase 2	62 participants (Actual)	Interventional	2008-03-31	Terminated(stopped due to Terminated due to discontinuation of Acular PF (investigational medication))
The Efficiency of Periarticular Multimodal Drug Injection in Pain Management Following Primary Unilateral Total Knee Arthroplasty: a Randomized Controlled Trial [NCT06112548]		80 participants (Anticipated)	Interventional	2023-11-01	Not yet recruiting
Pharmacokinetics of Anesthetics and Analgesics in Children and Adolescent [NCT03427736]		460 participants (Anticipated)	Observational	2018-12-13	Recruiting
A Randomized, Double-blinded, Placebo-controlled Study of Ketorolac Use in Pediatric Patients Undergoing Tonsillectomy [NCT03453541]	Phase 4	600 participants (Anticipated)	Interventional	2017-11-21	Recruiting
Wound Infiltration With Ketorolac Versus Lidocaine for Postoperative Analgesia After Total Abdominal Hysterectomy: a Prospective, Randomized, Double-blind Study. [NCT03394001]	Phase 4	80 participants (Actual)	Interventional	2018-01-01	Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00478036 (1) [back to overview]	Interocular Pressure
NCT00483717 (8) [back to overview]	The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point
NCT00483717 (8) [back to overview]	The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point
NCT00483717 (8) [back to overview]	The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point
NCT00483717 (8) [back to overview]	The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point
NCT00483717 (8) [back to overview]	The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point
NCT00483717 (8) [back to overview]	The Number of Treated Subjects Who Became Pain-free (International Headache Society Grade of 0 = no Pain) by Observation Time Point.
NCT00483717 (8) [back to overview]	The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point
NCT00483717 (8) [back to overview]	The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point
NCT00621530 (5) [back to overview]	Area of Hypersensitivity to Mechanical Stimuli Surrounding the Wound 48 Hours After Surgery
NCT00621530 (5) [back to overview]	McGill Pain Intensity
NCT00621530 (5) [back to overview]	McGill Affective Pain
NCT00621530 (5) [back to overview]	Present Pain Intensity
NCT00621530 (5) [back to overview]	Neuropathic Pain Symptom Inventory
NCT00638508 (20) [back to overview]	Pain Score on Coughing
NCT00638508 (20) [back to overview]	DROWSINESS
NCT00638508 (20) [back to overview]	DROWSINESS
NCT00638508 (20) [back to overview]	Pain Score at Rest
NCT00638508 (20) [back to overview]	Pain on Movement
NCT00638508 (20) [back to overview]	NAUSEA
NCT00638508 (20) [back to overview]	NAUSEA
NCT00638508 (20) [back to overview]	Morphine Equivalents Utilization
NCT00638508 (20) [back to overview]	Morphine Equivalents
NCT00638508 (20) [back to overview]	VOMITING
NCT00638508 (20) [back to overview]	Morphine Equivalents
NCT00638508 (20) [back to overview]	VOMITING
NCT00638508 (20) [back to overview]	PATIENT SATISFACTION
NCT00638508 (20) [back to overview]	Pain Scores on Movement
NCT00638508 (20) [back to overview]	Pain Scores on Coughing
NCT00638508 (20) [back to overview]	Pain Scores on Coughing
NCT00638508 (20) [back to overview]	Pain on Movement
NCT00638508 (20) [back to overview]	PATIENT SATISFACTION
NCT00638508 (20) [back to overview]	Pain Scores at Rest
NCT00638508 (20) [back to overview]	Pain Scores at Rest
NCT01001806 (1) [back to overview]	Peak Aqueous Penetration
NCT01021761 (1) [back to overview]	Aqueous PGE2 Inhibition
NCT01023724 (1) [back to overview]	Anterior Chamber Inflammation (Flare)
NCT01042093 (3) [back to overview]	Numerical Rating Scale (NRS) Pain Scores During Hospitalization.
NCT01042093 (3) [back to overview]	Knee Society Pain Scores at 6 Week Follow-up Appointment
NCT01042093 (3) [back to overview]	Narcotic Consumption During Hospitalization
NCT01242644 (8) [back to overview]	Pain Scale
NCT01242644 (8) [back to overview]	Pain Scale
NCT01242644 (8) [back to overview]	Number of Narcotic Pills and Morphine Sulfate Used
NCT01242644 (8) [back to overview]	Pain Scale
NCT01242644 (8) [back to overview]	Pain Score 8 Hours Post-operativley
NCT01242644 (8) [back to overview]	Number of Narcotic Pills and Morphine Sulfate Used
NCT01242644 (8) [back to overview]	Number of Narcotic Pills and Morphine Sulfate Used
NCT01242644 (8) [back to overview]	Number of Narcotic Pills and Morphine Sulfate Used
NCT01260883 (12) [back to overview]	Volume of Distribution for Ketorolac Isomers in 6-18 Month Old Infants
NCT01260883 (12) [back to overview]	Total Morphine Use in 6-18 Month Old Infants After Ketorolac or Placebo Intravenous Infusion After Surgery
NCT01260883 (12) [back to overview]	Peripheral Volume of Distribution for S- and R+ Ketorolac in 2-6 Month Old Infants
NCT01260883 (12) [back to overview]	Percent Time With Room Air Oximetry Saturations Under 90% in 2-6 Month Infants
NCT01260883 (12) [back to overview]	Morphine Use in 2-6 Month Old Infants Given Ketorolac or Placebo Following Surgery
NCT01260883 (12) [back to overview]	Ketorolac Stereo-isomer Volume of Distribution Peripheral in 6-18 Month Old Infants
NCT01260883 (12) [back to overview]	Central Volume of Distribution for S- and R+ Ketorolac in 2-6 Month Old Infants
NCT01260883 (12) [back to overview]	Clearance of S- and R+ Ketorolac in 6-18 Month Old Infants
NCT01260883 (12) [back to overview]	Clearance of S-ketorolac and R+ Ketorolac in 2-6 Month Old Infants Following Surgery
NCT01260883 (12) [back to overview]	Oximetry Saturation Under 90% After Ketorolac or Placebo Infusion in 6-18 Month Old Infants
NCT01260883 (12) [back to overview]	Half-life of Ketorolac Stereo-isomers in 6-18 Month Old Infants After Surgery
NCT01260883 (12) [back to overview]	Half-life of S- and R+ Ketorolac in 2-6 Month Old Infants
NCT01345162 (1) [back to overview]	Analgesic Efficacy
NCT01351090 (4) [back to overview]	Total MS Use in Milligrams by PCA From 24 Hours After the Start of Dosing Through 48 Hours
NCT01351090 (4) [back to overview]	Total MS Use in Milligrams by PCA From the Start of Dosing Through 48 Hours
NCT01351090 (4) [back to overview]	Pain Intensity Difference (PID) Scores
NCT01351090 (4) [back to overview]	Total Morphine Sulfate (MS) Use in Milligrams by Patient-controlled Analgesia (PCA) Through 24 Hours
NCT01355588 (4) [back to overview]	Area Under the Plasma Concentration-time Profile From Time Zero to the Last Quantifiable Post-dose (AUC 0-t)
NCT01355588 (4) [back to overview]	Area Under the Plasma Concentration-time Profile From Time Zero to Infinity (AUC 0-∞)
NCT01355588 (4) [back to overview]	Maximum Observed Plasma Concentration (Cmax)
NCT01355588 (4) [back to overview]	Time to Reach Maximum Plasma Concentration (Tmax)
NCT01363050 (9) [back to overview]	Tmin,ss (the Time to Minimum Concentration at Steady State)
NCT01363050 (9) [back to overview]	Tmax,ss (the Time to Maximum Concentration at Steady State)
NCT01363050 (9) [back to overview]	Tmax (the Time to Maximum Concentration)
NCT01363050 (9) [back to overview]	AUC 0-8h (the Area Under the Plasma Concentration-time Curve From Time 0 to 8 Hours Post-dose)
NCT01363050 (9) [back to overview]	MRT (the Mean Residence Time
NCT01363050 (9) [back to overview]	Cmin,ss (the Minimum Observed Plasma Concentration at Steady State)
NCT01363050 (9) [back to overview]	Cmax,ss (the Maximum Observed Plasma Concentration at Steady State)
NCT01363050 (9) [back to overview]	Cmax (the Maximum Observed Plasma Concentration)
NCT01363050 (9) [back to overview]	AUCτ (the Area Under the Plasma Concentration-time Curve Over the Dosing Interval at Steady-state)
NCT01363076 (7) [back to overview]	Tmax (The Time to Maximum Observed Plasma Concentration; ie. The Time at Which Cmax Occured)
NCT01363076 (7) [back to overview]	AUC 0-24 (the AUC From Time Zero to 24 Hours Post-dose
NCT01363076 (7) [back to overview]	Cmax (the Maximum Observed Plasma Concentration)
NCT01363076 (7) [back to overview]	MRT (Mean Residence Time)
NCT01363076 (7) [back to overview]	t1/2 (the Terminal Half-life, Where Possible)
NCT01363076 (7) [back to overview]	AUCinf (the AUC Time From Zero to Infinity, Where Possible)
NCT01363076 (7) [back to overview]	AUClast (the Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Last Quantifiable Timepoint Post-dose)
NCT01365611 (6) [back to overview]	Cmax (the Maximum Observed Plasma Concentration of Ketorolac Tromethamine)
NCT01365611 (6) [back to overview]	MRT (the Mean Residence Time of Ketorolac Tromethamine, Where Possible)
NCT01365611 (6) [back to overview]	t1/2z (the Terminal Half-life of Ketorolac Tromethamine, Where Possible)
NCT01365611 (6) [back to overview]	Tmax (the Time to Maximum Concentration of Ketorolac Tromethamine)
NCT01365611 (6) [back to overview]	AUC 0-t (the Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Last Quantifiable Time Point Post-dose of Ketorolac Tromethamine).
NCT01365611 (6) [back to overview]	AUC Inf (the AUC From Time Zero to Infinity, Where Possible)
NCT01365624 (6) [back to overview]	Tmax (Time to Reach Maximum Plasma Concentration)
NCT01365624 (6) [back to overview]	t1/2z (Terminal Half-life)
NCT01365624 (6) [back to overview]	MRT (Mean Residence Time)
NCT01365624 (6) [back to overview]	Cmax (Maximum Plasma Concentration)
NCT01365624 (6) [back to overview]	AUClast (Area Under the Plasma Concentration-time Profile From Time Zero to the Last Quantifiable Time Point Post-dose
NCT01365624 (6) [back to overview]	AUC (Area Under the Plasma Concentration-time Profile From Time 0 to Infinity
NCT01365650 (6) [back to overview]	AUC 0-∞ (the AUC From Time Zero to Infinity, Where Possible)
NCT01365650 (6) [back to overview]	AUC 0-t (the Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Last Quantifiable Time Point Post-dose)
NCT01365650 (6) [back to overview]	Cmax (the Maximum Observed Plasma Concentration)
NCT01365650 (6) [back to overview]	MRT (the Mean Residence Time)
NCT01365650 (6) [back to overview]	t1/2z (the Terminal Half-life, Where Possible)
NCT01365650 (6) [back to overview]	Tmax (the Time to Maximum Concentration)
NCT01806259 (2) [back to overview]	Overall Survival
NCT01806259 (2) [back to overview]	Recurrence-free Survival
NCT01901393 (6) [back to overview]	Efficacy of Pain Relief (Pain Intensity With Movement)
NCT01901393 (6) [back to overview]	Incidence of Serious Adverse Events
NCT01901393 (6) [back to overview]	Time to First Use of Rescue Med Will be Measured
NCT01901393 (6) [back to overview]	Patient Satisfaction
NCT01901393 (6) [back to overview]	Rescue Medication Use in Post-operative Period
NCT01901393 (6) [back to overview]	Efficacy of Pain Relief (Pain Intensity at Rest)
NCT02078492 (4) [back to overview]	Adverse Effect of Headache
NCT02078492 (4) [back to overview]	Adverse Effect of Nausea
NCT02078492 (4) [back to overview]	Pain Score at 30 Minutes
NCT02078492 (4) [back to overview]	Adverse Effect of Dizziness
NCT02112448 (2) [back to overview]	Length of Stay
NCT02112448 (2) [back to overview]	Total Morphine Dosage
NCT02312739 (5) [back to overview]	Change From Baseline in Patient Anxiety Scale After the Procedure
NCT02312739 (5) [back to overview]	Patient Satisfaction (5-point Likert Scale)
NCT02312739 (5) [back to overview]	Change From Baseline in Pain Scale Measurement During and After the Procedure
NCT02312739 (5) [back to overview]	Pain Scale Measurement - Maximum Pain Experienced
NCT02312739 (5) [back to overview]	Provider Ease of Insertion (0-100mm VAS)
NCT02313675 (2) [back to overview]	Postoperative Pain (Pain Scores From 0-10 Scale)
NCT02313675 (2) [back to overview]	Opioid Consumption (Number of Pills Taken)
NCT02358681 (11) [back to overview]	Percentage Change in Pain Score Between Baseline and One Hour
NCT02358681 (11) [back to overview]	Number of Participants Who Received Rescue Medications During Emergency Department Visit
NCT02358681 (11) [back to overview]	Time to Achieve Clinically Significant Reduction in Pain After Analgesic Administration (Pain Score)
NCT02358681 (11) [back to overview]	Number of Participants Who Used Rescue Medication(s) Within 24 Hours After Emergency Department Discharge
NCT02358681 (11) [back to overview]	Number of Participants Who Reported Sustained Headache Relief at 24-hour Follow-up
NCT02358681 (11) [back to overview]	Number of Participants Who Reported Sustained Headache Freedom at 24-hour Follow-up
NCT02358681 (11) [back to overview]	Number of Participants Who Reported Positive Overall Efficacy and Tolerability at 24-hour Follow-up
NCT02358681 (11) [back to overview]	Number of Participants Who Experienced Headache Relief During Emergency Department Visit
NCT02358681 (11) [back to overview]	Number of Participants Who Experienced Headache Freedom During Emergency Department Visit
NCT02358681 (11) [back to overview]	Change in Pain Score After Analgesic Administration (Faces Pain Scale - Revised (FPS-R)
NCT02358681 (11) [back to overview]	Adverse Events
NCT02658149 (5) [back to overview]	Opioid Usage In-hospital at 48 Hours
NCT02658149 (5) [back to overview]	Pain Score at 24-48 Hours
NCT02658149 (5) [back to overview]	Opioid Usage In-hospital at 24 Hours
NCT02658149 (5) [back to overview]	Pain Score at 3 Hours
NCT02658149 (5) [back to overview]	Pain Score at 3-24 Hours
NCT02902770 (1) [back to overview]	Pain Score at 30 Minutes
NCT03111381 (2) [back to overview]	Number of Participants With Complications
NCT03111381 (2) [back to overview]	Post-operative Pain
NCT03540030 (16) [back to overview]	ASES
NCT03540030 (16) [back to overview]	Veterans RAND 12 Item Health Survey (VR-12©) Physical Health Subscore, and Mental Health Subscore
NCT03540030 (16) [back to overview]	Simple Shoulder Test
NCT03540030 (16) [back to overview]	Post Op Pain
NCT03540030 (16) [back to overview]	Morphine Use
NCT03540030 (16) [back to overview]	Veterans RAND 12 Item Health Survey (VR-12©) Physical Health Subscore, and Mental Health Subscore
NCT03540030 (16) [back to overview]	Pain Satisfaction
NCT03540030 (16) [back to overview]	Pain Satisfaction
NCT03540030 (16) [back to overview]	Nausea
NCT03540030 (16) [back to overview]	Nausea
NCT03540030 (16) [back to overview]	Falls
NCT03540030 (16) [back to overview]	Falls
NCT03540030 (16) [back to overview]	Constipation
NCT03540030 (16) [back to overview]	Constipation
NCT03540030 (16) [back to overview]	Additional Post Op Pain
NCT03540030 (16) [back to overview]	Simple Shoulder Test
NCT03584373 (7) [back to overview]	Current Pain Intensity Level
NCT03584373 (7) [back to overview]	Average Pain Intensity Level
NCT03584373 (7) [back to overview]	Peak Pain Intensity Level
NCT03584373 (7) [back to overview]	Rates of Constipation
NCT03584373 (7) [back to overview]	Satisfaction With Pain Relief
NCT03584373 (7) [back to overview]	Unused Medications - Proportion of Prescribed Pills Unused at 1 Week Post-Surgery
NCT03584373 (7) [back to overview]	Perception of an Acceptable Pain Intensity Level
NCT04766996 (2) [back to overview]	Nebraska Interprofessional Education Attitude Scale (NIPEAS) Score for Professional Staff Arm
NCT04766996 (2) [back to overview]	Total Post-operative Opioid Requirements With Non-opioid Drug Regimen

Interocular Pressure

IOP, measured by Goldmann applanation tonometry (NCT00478036)
Timeframe: 8 weeks

Intervention	mmHg (Mean)
	Baseline	Day 1	Week 1	Week 4	week 8
Acular LS	16.1	11.6	15.2	14.3	14.0
Pred Forte	17.0	12.4	15.7	14.0	15.0
Refresh Tears	17.8	13.4	15.6	14.6	15.8

Intervention	units on a scale (Mean)
	Postoperative: 2 days	Postoperative: 2 months	Postoperative: 6 months
Ketorolac	11	2.3	1.4
Placebo	10	3.1	1.2

Intervention	units on a scale (Mean)
	Preoperative	Postoperative: 2 days	Postoperative: 2 months	Postoperative: 6 months
Ketorolac	1.7	2.1	0.6	0.4
Placebo	1.6	2.5	0.2	0.1

Intervention	scores on a scale 0-10 (Mean)
	Vas Pain Scale - 1 Hour Post Op	Vas Pain Scale - 8 Hour Post Op	Vas Pain Scale - 16 Hour Post Op	Vas Pain Scale - 24 Hour Post Op	Vas Pain Scale - 32 Hour Post Op	Vas Pain Scale - 40 Hour Post Op	Vas Pain Scale - 48 Hour Post Op	Vas Pain Scale Preoperatively
ROP/EPI	1.60	2.82	2.41	2.96	3.13	2.80	2.11	2.13
ROP/EPI/CLO	2.67	3.93	2.75	3.63	3.62	3.28	2.56	2.43
ROP/EPI/TOR	1.90	1.52	2.22	2.56	2.66	2.35	1.97	2.47
ROP/EPI/TOR/CLO	1.06	1.52	1.85	2.33	2.18	2.54	2.41	1.93

Intervention	mg (Mean)
	Morphine Equivalent Day of Surgery	Morphine Equivalent Post Operative Day 1	Morphine Equivalent Post Operative Day 2	Morphine Equivalent Post Operative Day 3
ROP/EPI	52.50	51.08	36.76	15.54
ROP/EPI/CLO	55.20	64.61	50.07	21.97
ROP/EPI/TOR	43.09	47.95	42.69	18.72
ROP/EPI/TOR/CLO	46.92	46.54	40.71	20.45

Intervention	units on a scale (Mean)
Pain Pump , Injectable Medication	3.3
Saline Pain Pump , Injectable Medication	4.05
Injectable Medication Only	3.13

Intervention	units on a scale (Mean)
Pain Pump , Injectable Medication	1.75
Saline Pain Pump , Injectable Medication	3.23
Injectable Medication Only	3.06

Intervention	Number of pills (Mean)
Pain Pump , Injectable Medication	3.41
Saline Pain Pump , Injectable Medication	3.8
Injectable Medication Only	3.8

Intervention	units on a scale (Mean)
Pain Pump , Injectable Medication	1.81
Saline Pain Pump , Injectable Medication	3.17
Injectable Medication Only	2.26

Intervention	ml (Mean)
S- Ketorolac Volume Distribution Central	2320
R+ Ketorolac Volume Distribution Central	1200

Intervention	ml (Mean)
S- Ketorolac Volume Distribution, Peripheral	341
R+ Ketorolac Volume Distribution, Peripheral	658

Intervention	area in centimeters squared (Median)
Ketorolac	0
Placebo	0

Intervention	ml (Mean)
S- Ketorolac Volume Distribution, Central	1480
R+ Ketorolac Volume Distribution, Central	992

Intervention	mg (Mean)
Ketorolac IN 10 mg	28.25
Ketorolac IN 30 mg	23.11
Placebo Vehicle IN	32.61

Intervention	mg (Mean)
Ketorolac IN 10 mg	78.66
Ketorolac IN 30 mg	61.39
Placebo Vehicle IN	87.87

Intervention	units on a scale (Mean)
Ketorolac IN 10 mg	34.1
Ketorolac IN 30 mg	38.9
Placebo Vehicle IN	29.1

Intervention	mg (Mean)
Ketorolac IN 10 mg	54.32
Ketorolac IN 30 mg	37.77
Placebo Vehicle IN	56.45

Intervention	ng*h/mL (Mean)
Ketorolac Tromethamine	8440.6
Ketorolac Tromethamine With 4% Lidocaine Hydrochloride (HCl)	7856.0
Ketorolac Tromethamine With 5% Lidocaine HCl	7561.5
Ketorolac Tromethamine With 6% Lidocaine HCl	8103.8

Intervention	ng*h/mL (Mean)
Ketorolac Tromethamine	9061.9
Ketorolac Tromethamine With 4% Lidocaine Hydrochloride (HCl)	8694.5
Ketorolac Tromethamine With 5% Lidocaine HCl	8086.8
Ketorolac Tromethamine With 6% Lidocaine HCl	8677.6

Intervention	ng/mL (Mean)
Ketorolac Tromethamine	2059.6
Ketorolac Tromethamine With 4% Lidocaine Hydrochloride (HCl)	1963.1
Ketorolac Tromethamine With 5% Lidocaine HCl	1799.9
Ketorolac Tromethamine With 6% Lidocaine HCl	2048.5

Intervention	hours (Median)
Ketorolac Tromethamine	0.510
Ketorolac Tromethamine With 4% Lidocaine Hydrochloride (HCl)	0.500
Ketorolac Tromethamine With 5% Lidocaine HCl	0.390
Ketorolac Tromethamine With 6% Lidocaine HCl	0.410

Intervention	hr (Median)
Ketorolac Tromethamine (15 mg)	0.720
Ketorolac Tromethamine (30 mg)	0.780

ketorolac tromethamine

Description

Cross-References

Synonyms (173)

Research Excerpts

Overview

Effects

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (1)

Protein Targets (26)

Potency Measurements

Inhibition Measurements

Biological Processes (219)

Molecular Functions (63)

Ceullar Components (42)

Bioassays (75)

Research

Studies (570)

Market Indicators

Research Demand Index: 84.13

Study Types

Clinical Trials (133)

Trial Overview

Trial Outcomes

Interocular Pressure

The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point

The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point

The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point

The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point

The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point

The Number of Treated Subjects Who Became Pain-free (International Headache Society Grade of 0 = no Pain) by Observation Time Point.

The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point

The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point

Area of Hypersensitivity to Mechanical Stimuli Surrounding the Wound 48 Hours After Surgery

McGill Pain Intensity

McGill Affective Pain

Present Pain Intensity

Neuropathic Pain Symptom Inventory

Pain Score on Coughing

DROWSINESS

DROWSINESS

Pain Score at Rest

Pain on Movement

NAUSEA

NAUSEA

Morphine Equivalents Utilization

Morphine Equivalents

VOMITING

Morphine Equivalents

VOMITING

PATIENT SATISFACTION

Pain Scores on Movement

Pain Scores on Coughing

Pain Scores on Coughing

Pain on Movement

PATIENT SATISFACTION

Pain Scores at Rest

Pain Scores at Rest

Peak Aqueous Penetration

Aqueous PGE2 Inhibition

Anterior Chamber Inflammation (Flare)

Numerical Rating Scale (NRS) Pain Scores During Hospitalization.

Knee Society Pain Scores at 6 Week Follow-up Appointment

Narcotic Consumption During Hospitalization

Pain Scale

Pain Scale

Number of Narcotic Pills and Morphine Sulfate Used

Pain Scale

Pain Score 8 Hours Post-operativley

Number of Narcotic Pills and Morphine Sulfate Used

Number of Narcotic Pills and Morphine Sulfate Used

Number of Narcotic Pills and Morphine Sulfate Used

Volume of Distribution for Ketorolac Isomers in 6-18 Month Old Infants

Total Morphine Use in 6-18 Month Old Infants After Ketorolac or Placebo Intravenous Infusion After Surgery

Intervention	ng•h/mL (Mean)
Ketorolac Tromethamine (15 mg)	9600.5
Ketorolac Tromethamine (30 mg)	11317.2

Intervention	ng/mL (Mean)
Ketorolac Tromethamine (15 mg)	1153.9
Ketorolac Tromethamine (30 mg)	1625.3

Intervention	hr (Mean)
Ketorolac Tromethamine (15 mg)	9.664
Ketorolac Tromethamine (30 mg)	6.727

Intervention	hr (Mean)
Ketorolac Tromethamine (15 mg)	6.678
Ketorolac Tromethamine (30 mg)	5.031

Intervention	ng•h/mL (Mean)
Ketorolac Tromethamine (15 mg)	10590.7
Ketorolac Tromethamine (30 mg)	11949.5

Intervention	ng•h/mL (Mean)
Ketorolac Tromethamine (15 mg)	9308.2
Ketorolac Tromethamine (30 mg)	10662.1

Intervention	ng/mL (Mean)
Ketorolac Tromethamine (Given Alone)	2128
Fluticasone Propionate + Ketorolac Tromethamine	1948

Intervention	hours (Mean)
Ketorolac Tromethamine (Given Alone)	7.05
Fluticasone Propionate + Ketorolac Tromethamine	6.53

Intervention	hours (Mean)
Ketorolac Tromethamine (Given Alone)	5.95
Fluticasone Propionate + Ketorolac Tromethamine	5.49

Intervention	hours (Median)
Ketorolac Tromethamine (Given Alone)	0.750
Fluticasone Propionate + Ketorolac Tromethamine	0.750